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ABSTRACT 
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Cornelia de Lange syndrome (CdLS) is a rare disorder characterized by an extensive clinical 
heterogeneity. The main features of the syndrome are characteristic facial dysmorphisms and a 
variable level of intellectual disability, growth retardation and developmental delay. Though, 
the number and severity of the clinical signs vary among patients. An extensive genetic 
heterogeneity partially accounts for the reported clinical variability. Mutations in different 
cohesin-associated proteins are in fact responsible for the onset of the syndrome. The known 
CdLS-genes include NIPBL, SMC1A, SMC3, RAD21 and HDAC8. Alterations in the cohesin 
loader NIPBL are found in more than half of CdLS cases and are associated with a classical 
phenotype and with a high frequency of limb malformations. In addition, mosaicism has been 
proven to play an important role in association with NIPBL. Mutations in the structural 
elements SMC1A, SMC3 and RAD21 and in the regulator HDAC8 account for about 10-15% of 
CdLS cases. The phenotype of those patients who harbor mutations in these genes is usually 
milder or atypical. The five genes all together, also taking into account the role of mosaicism, 
can explain about 70% of CdLS cases. 
In an internationally assembled cohort of patients we were able to identify 109 mutations in 
NIPBL, 8 mutations in SMC1A, 15 mutations in SMC3 and 11 mutations in HDAC8, thus 
increasing the total number of mutations so far described for CdLS. In addition, by the use of 
next generation sequencing techniques we were able to identify mutations in five genes 
different from cohesin in six unrelated patients with a clinical diagnosis of CdLS. The five 
genes include those encoding for different subunits of the chromatin remodeling complex 
named SWI/SNF and for the transcriptional repressor ANKRD11. Mutations in these genes 
have been so far associated to Coffin-Siris syndrome and KBG syndrome, respectively. 
Protein-protein interaction experiments also showed a direct interaction of the SWI/SNF 
subunit SMARCB1 with the cohesin-related proteins NIPBL and SMC3. These direct link 
between cohesin and SWI/SNF subunits indicate that mutations affecting the two protein 
complexes might determine the deregulation of overlapping sets of genes. 
Our newly identified variants contribute to a better understanding of the correlation between 
genotype and phenotype in the presence of mutations in the known-CdLS genes. 
Notwithstanding, different pehotypes have been observed in patients carrying the same DNA 
alteration, hence suggesting that environmental factors may play an important role in the 
delineation of the observed clinical features. Additionally, the identification of mutations in 
chromatin-associated factors responsible for syndromes different from CdLS indicate the 
existence of a broad pleiotropy that should be taken into account while assessing the clinical 
and molecular diagnosis. 
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Furthermore, we investigated the molecular mechanisms underlying the syndrome in the 
presence of missense substitutions or small in-frame deletions in SMC1A, a X-linked gene that 
localizes in a region of the X-chromosome that partially escapes X-inactivation in humans. Our 
expression analysis revealed that the transcript is expressed at higher levels in females as 
compared to males, and that there are no differences in the expression of the SMC1A protein 
between healthy and affected females. In addition, pyrosequencing analysis showed that CdLS 
female patients harboring mutations in SMC1A tend to express the wild type allele at higher 
levels as compared to the mutant allele. All together, these data suggests that the pathogenesis 
of the syndrome in the presence of mutations affecting SMC1A which do not disrupt the 
reading frame might be linked to a dominant negative effect exerted by the mutant protein on 
the wild type.  
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CORNELIA DE LANGE SYNDROME 
Cornelia de Lange syndrome (CdLS, OMIM #122470, 300590, 610759, 300882, and 614701) 
is a multisystem developmental disorder characterized by a dominant mode of inheritance. In 
the majority of cases it occurs de novo; though, also some familial cases have been described. 
 
HISTORY 
In 1933 the Dutch pediatrician Cornelia de Lange recognized and described for the first time in 
the “Archives de Medicine des Enfants” some comparable clinical features observed in two 
unrelated patients (de Lange, 1933). 
The first patient (Fig.1a) was a 17-months old girl hospitalized at the Emma Children’s 
Hospital of Amsterdam in 1932 because of bronchopneumonia. The child was born at 40 weeks 
of gestation with a birth weight of 1250 g; she presented with growth retardation, 
microcephaly, remarkably unusual facial features and feeding difficulties that persisted during 
the first year of life. 
The second patient (Fig.1b), hospitalized few weeks after, shared the growth impairment and 
the digestive disorder with the first girl. Nevertheless, the most striking resembling features 
were related to the facies.  
 
 
Figure 1. First two patients with the “Typus Degenerativus Amstelodamensis”described from doctor de Lange in 1933 
 
For both cases, doctor de Lange made a highly detailed description of the clinical features and 
assigned to this phenotype the definition of “Typus Degenerativus Amstelodamensis” (de 
Lange, 1933). 
During the following years a discreet number of patients with an analogous clinical 
presentation was described in the literature. Then, in 1964, Opitz and colleagues associated for 
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the first time the phenotype described by doctor de Lange in 1933 with the one described by the 
German doctor Winfried Robert Clemens Brachmann in a paper of 1916 titled “Ein Fall von 
symmetrischer Monodaktylie durch Ulnadefekt, mit symmetrischer Flughaurbildung in den 
Ellenbogen sowie anderen Abnormalitaten”, that likely represents the first description of the so 
called “Typus Degenerativus Amstelodamensis” syndrome. Because of this, Opitz and 
colleagues named the new clinical entity Brachmann-de Lange syndrome (Brachmann, 1916; 
Opitz et al., 1964). Today, the syndrome is mainly known and named as Cornelia de Lange 
syndrome (CdLS). Since 1964, many cases with similar features have been described, and a 
remarkable clinical heterogeneity of the syndrome has emerged. 
 
CLINICAL FEATURES 
Cornelia de Lange syndrome (CdLS) is characterized by distinct clinical features that involve 
different organs with variable extent; nevertheless, the muscoloskeletal, gastrointestinal, and 
nervous systems represent the most frequently affected systems (Kline et al., 2007). 
The incidence of CdLS in the population has been discussed for several years because of the 
difficulties in the formulation of the diagnosis, that is mainly based on clinical observations. 
The first assessment of the frequency was performed in 1967 by Pearce and Pitt, who estimated 
the prevalence to be around 1:100.000 (Pearce and Pitt, 1967). Currently, public scientific 
databases (OMIM, GeneReviews and GeneticsHomeReference) and more recent papers attest 
the incidence between 1:10.000 and 1:40.000 live births (Kline et al., 2007; Barisic et al., 
2008). 
To date, minimal diagnostic criteria have been established based on the consensus of the 
Scientific Advisory Committee of the World CdLS Federation (SAC) and the Clinical Advisory 
Board of the CdLS Foundation USA (CAB). A CdLS diagnosis requires the presence of 
specific facial features in combination with the involvement of at least two other systems 
responsible for growth, development or behavior (Kline et al., 2007). 
A scoring system (Table 1) is also available to determine the severity of the phenotype. This 
system assigns a score to each of the following categories: birth weight, age of sitting 
independently, age of walking independently, age of the first word, presence or absence of 
upper limbs malformations and presence or absence of hearing loss. Scores higher than 22 are 
associated with a severe phenotype, while scores between 15 and 22 indicate a moderate 
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presentation of CdLS; lastly, patients with a score lower than 15 are affected by a mild form of 
the syndrome (Table 1; Kline et al., 2007). 
 
 
Table 1. Scoring system that allows the classification of CdLS into three different categories, namely severe, moderate and 
mild (from Kline et al., 2007) 
 
Prenatal diagnosis and auxological data 
Despite the incidence of premature births is higher than in the normal population (30%), 
relevant obstetric complications rarely occur during CdLS pregnancies. As the majority of 
CdLS cases are de novo, the recurrence risk for asymptomatic parents has been estimated to be 
approximately 1.5% (Jackson et al., 1993). Nevertheless, in the presence of more than one 
affected child within one family, the existence of germline mosaicism should be considered 
(Slavin et al., 2012; Mariani et al., 2013). 
High-resolution ultrasound examination appears to be the best technique for a prenatal 
diagnosis of the syndrome. Intra-uterine growth retardation (IUGR) and limb malformations are 
the most discernible features, but reported ultrasound findings also include microcephaly and 
diaphragmatic hernia (Sekimoto et al., 2000; Huang and Porto, 2002). In some cases it was also 
possible to notice micrognathia with prominent maxilla and a depressed nasal bridge with 
anteverted nares, features that define the unique facial profile of CdLS (Clark et al., 2012). 
Maternal serum screening might also be performed: the levels of the Pregnancy-Associated 
Plasma Protein-A (PAPP-A) have shown to be reduced during the first and second trimester in 
pregnancies affected by CdLS; nevertheless, this biomarker is not specific for CdLS 
(Westergaard et al., 1983; Aitken et al., 1999; Arbuzova et al., 2003). Lastly, an increased fetal 
nuchal translucency during the first trimester has also been observed (Sekimoto et al., 2000; 
Huang and Porto, 2002). 
Auxological data are highly peculiar for CdLS; for this reason, specific charts are used to 
define the growth parameters of patients, who are usually characterized by pre- and postnatal 
growth retardation (Kline et al., 2007). In point of fact, the body parameters at birth are 
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frequently under the 10th centile, with an average weight of 2.28 kg, an average length of 45.5 
cm and an average head circumference of 30.9 cm. The growth curve runs parallel to the one of 
the healthy population but tends to decrease under the 5th centile during early childhood (Kline 
et al., 1993a; Kline et al., 1993b). During adulthood, the average weight and height are 47.6 kg 
and 156 cm for men, and 30.5 kg and 131 cm for women. The head circumference can reach 
the average value of 49 cm, consistent with a significant microcephaly (Kline et al., 1993a; 
Kline et al., 1993b). 
 
Facial dysmorphisms 
The facial features are the most recognizable findings in CdLS (Fig.2). Patients usually present 
with a short neck and a low anterior and posterior hairline. Eyebrows are typically arched, 
hypertrophic and fused above the bridge of the nose (synophrys). Eyelashes are thick, long and 
curly. Narrow palpebral fissures and ptosis are also reported. The midface is usually flattened 
and characterized by the presence of a short nose presenting with a depressed bridge and 
anteverted nares. Beneath, the philtrum is frequently smooth and long. Exemplary oral features 
include thin lips with down-turned commissures, downslanting superior lip, a high and arched 
palate, small and widely spaced teeth and micrognathia (Jackson et al., 1993).  
 
Figure 2. Typical facies observed in four patients with CdLS. These patients present with a variable degree of severity and are 
placed from the mildest to the most severe. Though, the striking facial features typical for CdLS are discernible in all of them 
(adapted from Liu and Krantz, 2009) 
 
Low-set dysplastic ears are also observed with a high frequency. The ear canal is often stenotic 
or narrow, thus causing predisposition to otitis media and sinusitis (Jackson et al., 1993).  
The facial features tend to evolve during aging: the face usually lengthens and becomes 
coarser. In some cases, the facial appearance also becomes less typical with age. For this 
reason, patients with a mild presentation of the syndrome would have been difficult to diagnose 
as CdLS if the clinical evaluation would have occurred in adulthood (Kline et al., 2007). 
Premature aging has also been reported (Kline et al., 2007). 
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Muscoloskeletal system 
The muscoloskeletal system is the district with the highest number of alterations: almost all 
patients present with upper limbs anomalies that range from the presence of small hands to the 
presence of severe reductions or malformations (Fig.3). Typical findings are disproportional 
shortening of the first metacarpal, proximally placed thumbs, brachydactyly, clinodactyly of the 
fifth finger, radial head dislocation, radioulnar synostosis and incomplete elbow extension 
(Jackson et al., 1993). 
 
 
Figure 3. Examples of upper limbs anomalies observed in CdLS patients, placed from the mildest to the most severe: almost all 
patients present with small hands, but in some cases absence of digits or of the entire forearms are also observed (adapted 
from Liu and Krantz, 2009) 
 
Lower extremities are usually less affected; the feet are small in almost all cases, and 
syndactyly of the second and third toes are frequently observed (Jackson et al., 1993). 
Other orthopedic complications include scoliosis, development of bunions, tight Achilles 
tendons, cervical malformations, pectum excavatum and hip dislocation or dysplasia, that 
occurs in 10-15% of patients and normally requires surgery during childhood. Osteoporosis 
may appear earlier than expected (Jackson et al., 1993). 
 
Gastrointestinal system 
Feeding problems are typical during infancy and young childhood, and can be caused by 
micrognathia, cleft palate and decreased muscle tone in the oral area. In addition, 
gastroesophageal reflux disease (GERD) is observed in more than 90% of patients and often 
requires surgical intervention (Luzzani et al., 2003). 
Malrotation, diaphragmatic hernia, increased risk for volvulus formation and intestinal 
obstruction and pyloric stenosis have also been frequently reported (Masumoto et al., 2001). 
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Cardiac system 
Congenital heart defects are observed in about 25% of CdLS patients. Ventriculo-septal defects 
or atrial-septal defects are the most commonly represented, but tetralogy of Fallot, pulmonic 
stenosis and hypoplastic left heart syndrome are also frequent (Jackson et al., 1993; Metha and 
Ambalavanan, 1997; Tsukahara et al., 1998; Kline et al., 2007). 
 
Genitourinary system 
Renal dysfunctions and malformations can be seen in approximately 40% of CdLS patients and 
include pelvic dilatation, vesiculoureteral reflux and renal dysplasia. Male patients frequently 
present hypoplastic genitalia and cryptorchidism; other common findings are hypospadias and 
micropenis. On the other hand, small labia majora and abnormally formed uteri can be 
observed in females. Fertility is decreased in severely affected individuals (Jackson et al., 
1993). 
 
Other malformations 
Ophthalmologically, almost all patients present peripapillary pigmentation. Other common 
findings are myopia, blepharitis, ptosis and mild forms of microcornea. Nystagmus, cataract, 
glaucoma and nasolacrimal duct obstruction have been reported with a lower frequency 
(Jackson et al., 1993). 
Vestibular and auditory anomalies include both conductive and sensorineural hearing loss 
together with recurrent otitis media and sinusitis (Marchisio et al., 2014). 
Neurologically, hypoplasia of the cerebellar vermis, enlarged ventricles particularly at the basal 
cisterns and atrophy of the white matter are frequently observed (Kline et al., 2007). 
Neurofibrillary tangles inside neurons, myelination defects and gyral structural abnormalities 
were also reported during autopsies (Yamaguchi K and Ishitobi F, 1999). Patients also present 
with high pain tolerance, which might be linked to peripheral neuropathy (Kline et al., 2007). 
Seizures are the main neuropathological manifestation. Though, no specific EEG patterns have 
been described and the seizures are usually well managed with standard medical treatments 
(Verrotti et al., 2013). The gait of those patients who achieve walking is often wide-based 
(Kline et al., 2007). 
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Patients often present with sleep disturbances, namely frequent awakenings, reduced need of 
sleeping with an average sleeping time of 2-4 hours per night, and ability to remain awake for a 
longer time compared to the normal population (Berney et al., 1999). 
The presence of diaphragmatic hernia is infrequent but important to mention because of the 
severe clinical implications (Masumoto et al., 2001). 
Generalized hypertrichosis is also one of the main manifestations of CdLS, particularly 
regarding the face, back and extremities; cutis marmorata is also another frequent finding. 
Small nipples and umbilicus have also been observed (Jackson et al., 1993). 
Puberty usually begins at ages 12-13 for girls and 13-14 for boys, slightly later if compared 
with the average onset of the healthy population (Basile et al., 2007). Menstrual cycles are 
observed in 76% of female patients, even though frequently irregular. Breast development is 
reported for 78% of the patients. Fertility is unaffected for those patients with a mild 
presentation of the syndrome (Kline et al., 2007). 
Obesity in association with type II diabetes has also been described (Kline et al., 2007). 
 
Cognitive impairment 
Cognitive impairment is always observed with an average IQ around 50. Nevertheless, the 
severity of the disability is highly variable: both borderline cases characterized by mild learning 
disabilities and severe impairments have in fact been reported. Learning continues throughout 
life without evidence of regression, but patients often need supervised living (Jackson et al., 
1993).  
Developmental delay is also a main feature of CdLS and speech acquisition is usually more 
severely affected than the motor development. Perceptual organization and visual-spatial 
memory are more preserved (Kline et al., 2007). Based on the period of language acquisition, 
patients are divided into four categories: 
• Talkers (3-4%): the psychomotor development is almost normal and they spontaneously 
start talking 
• Late talkers (35-40%): they sit independently after 18 months and walk independently 
after 30 months. They formulate the first words between four and eight years of age. 
They normally present with attention deficits 
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• Limited talkers (20-25%): they show a very slow psychomotor development, and 
pronounce the first words between seven and ten years of age; the ability to combine 
words appears after 10 years of age 
• NonTalkers (25-30%): they usually present with a very severe phenotype, including 
limb anomalies, hearing loss, autistic features and inability to walk before five years of 
age. They are unable to speak.  
 
Behavioral problems 
Almost all patients show behavioral issues that are usually caused or aggravated by physical 
complications. The following problems have been frequently reported: obsessive-compulsive 
disorders, self-injurious behavior, short attention span, attention deficit disorder with or without 
hyperactivity, depression, extreme shyness and autistic features (Basile et al., 2007). Many of 
these behavioral issues are thought to be secondary to frustration due to the inability to 
communicate or to the presence of GERD (Basile et al., 2007). 
Social and environmental interactions are achieved at variable degrees (Berney et al., 1999). 
 
Prognosis 
The prognosis is usually good in the absence of major malformations and life expectancy is 
estimated to be 10-20 years shorter compared to the healthy population, depending on the 
number and severity of the clinical signs (Coppus, 2013). 
The most common causes of death are mainly connected to gastrointestinal complications like 
diaphragmatic hernia, aspiration pneumonia complicated by GERD and volvulus at older ages 
(Schrier et al., 2011).  
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MOLECULAR BASIS: THE COHESIN COMPLEX 
CdLS is caused by mutations in different subunits or regulators of the cohesin complex; 
therefore, it falls within the category of the so called cohesinopathies (Krantz et al., 2004; 
Tonkin et al., 2004; Musio et al., 2006; Deardorff et al., 2007; Deardorff et al., 2012a; 
Deardorff et al., 2012b). 
Cohesin is a chromatin-associated multisubunit protein complex characterized by a high level 
of conservation during evolution. Cohesin was originally identified for its role in mediating 
sister chromatid cohesion during both meiosis and mitosis. Nevertheless, several studies have 
demonstrated an important role of the complex in different cellular processes including DNA 
repair, chromatin remodeling, regulation of gene expression and long-range interactions 
between distant genomic regions (Uhlmann, 2008; Sjögren and Ström, 2010; Cuylen and 
Haering, 2011; Dorsett, 2011; Feeney et al., 2012; Sofueva and Hadjur, 2012). Consequently, 
cohesin plays a very important role in the maintenance of genomic stability.  
Interestingly, cell lines of CdLS patients do not display cohesion defects. This finding suggests 
that the etiopathology of CdLS is probably not linked to the disruption of cohesion between 
sister chromatids but to the inability of the cohesin complex to mediate more dosage-sensitive 
cellular functions (Dorsett and Krantz, 2009). 
 
ARCHITECTURE OF THE COHESIN COMPLEX 
 
Figure 4. Architecture of the SMC proteins and of the cohesin complex (adapted from Onn et al., 2008) 
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The cohesin complex consists of four core subunits: SMC1A, SMC3, the α-kleisin protein 
RAD21 and the HEAT-repeat containing proteins STAG1 or STAG2 (Fig.4; Guacci et al., 
1997; Michaelis et al., 1997; Losada et al., 1998; Nasmyth and Haering, 2005). 
SMC1A (OMIM #300040, Xp11.22) and SMC3 (OMIM #606062, 10q25.2) are members of 
the Structural Maintenance of Chromosome (SMC) family, a very large family of ATPases 
characterized by a peculiar structure: one ATPase domain is localized at both the N- and C-
termini of the proteins and the two domains are then connected to each other through a long α-
helix. During the folding process, the α-helix bends on itself at the central hinge domain, thus 
forming 40 nm of anti-parallel coiled-coil structure. The bending of the α-helix brings the 
ATPases at the N- and C-termini close to each other, generating a globular ATPase head 
domain (Haering et al., 2002). By interacting through their respective hinge domains, SMC1A 
and SMC3 constitute the heterodimer that represents the core of the cohesin complex. The 
heads of both proteins are physically connected to RAD21, thus determining the generation of a 
tripartite ring structure. RAD21 (OMIM #606462, 8q24.11) belongs to the α-kleisin family; 
kleisin is a word that comes from the Greek language and means closure. In fact, RAD21 
determines the closure of the cohesin ring by bridging the head domains of the SMC proteins. 
Particularly, the N-terminus of RAD21 binds to the head domain of SMC3, whereas its C-
terminus interacts with the ATPase domain of SMC1A (Haering et al., 2002). Hence, SMC1A 
and SMC3 bind to each other directly through their respective hinge domains and indirectly 
through RAD21 at their head domains. The association of the SMC proteins with RAD21 
requires ATP: the binding of ATP determines the closure of the ring while its hydrolysis is 
needed for the dissociation of the complex (Arumugam et al., 2003; Weitzer et al., 2003). 
The fourth subunit of the cohesin complex, known as Stromalin Antigen (STAG), interacts 
with RAD21 and contains HEAT repeats that are important for protein-protein interactions 
(Neuwald and Hirano, 2000; Gruber et al., 2003). The functional role of this last subunit and of 
its HEAT repeats is still poorly understood. Vertebrates present two different isoforms of the 
STAG subunit, but the cohesin complex can contain only one subunit per time. STAG1-
containing cohesin seems to be responsible for transcriptional regulation and replication of 
telomeres, whereas complexes containing the STAG2 subunit are mainly involved in sister 
chromatid cohesion (Losada et al., 2000). 
It is worth to be noted that the meiotic cohesin complex differs from the mitotic one: in 
meiosis, the RAD21 subunit is substituted by the paralog REC8, while the STAG1/2 subunits 
are replaced by the protein STAG3. 
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COHESIN-ASSOCIATED PROTEINS 
In addition to the core subunits, many other cohesin-associated proteins have been identified 
that modulate cohesin activity and function (Table 2). 
The heterodimeric protein complex formed by NIPBL and MAU2 is the main regulator of 
cohesin and is responsible for the the loading of cohesin onto DNA (Krantz et al., 2004; Tonkin 
et al., 2004).  
NIPBL (OMIM #608667, 5p13.2) is the homologous of the Drosophila melanogaster Nipped-B 
gene and of the Saccharomyces cerevisiae Scc2 gene (Sister Chromatid Cohesion). The protein 
encoded by NIPBL, named Delangin, belongs to an evolutionary conserved family of proteins 
called adherins (Krantz et al., 2004; Tonkin et al., 2004). The human gene consists of 47 exons, 
while the coding sequence extends from exon 2 to exon 47 and can produce two main isoforms: 
the longer delangin-A (2804 aa) and the shorter delangin-B (2697 aa), that does not include 
exon 47 and results from the translation of an additional fragment of exon 46 (Krantz et al., 
2004; Tonkin et al., 2004). 
 
Figure 5. Structural organization of the NIPBL protein. The different domains of NIPBL and their localization are shown 
together with the amino acid sequences of the NIPBL specific repeats (from Yan et al., 2006) 
 
The amino acid sequence of NIPBL indicates different functional domains (Fig.5). From the N-
terminus to the C-terminus, the following domains are predicted: one caldesmon domain, one 
calponin domain, two calmodulin-binding motifs, one nuclear localization signal, one nuclear 
export signal, five HEAT repeats and one DNA binding domain (Yan et al., 2006). The 
caldesmon, calponin and calmodulin domains are so called for their analogy with the Ca2-
dependent proteins CALD1, CNN1 and calmodulin, that are involved in the contractility of the 
smooth muscle (Winder and Walsh, 1993). The HEAT repeats have instead been proven to play 
an important role in the establishment of cohesion, since they have been identified in other 
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cohesin-associated proteins. These repeats consist of sequences of 34-43 aa that are organized 
in clusters and are known for their role in mediating protein-protein interactions (Neuwald and 
Hirano, 2000). 
Northern Blot analyses have shown that the NIPBL transcript is ubiquitously expressed. 
Though, the level of transcription is tissue-specific. Wheras high levels of NIPBL expression 
are observed in cardiac and skeletal muscles, the expression appear to be very low in brain, 
lungs and intestine (Krantz et al., 2004; Tonkin et al., 2004). 
The adherin NIPBL is involved in various cellular processes including gene expression 
regulation, sister chromatid cohesion and DNA repair. It was also shown to be functionally 
linked to chromatin remodeling complexes through the direct interaction with the histones 
deacetylases (Jahnke et al., 2008). Its role in the regulation of gene expression has been well 
documented in Drosophila melanogaster. Here, the homolog Nipped-B activates the 
transcription of the cut, ultrabithorax and Notch signaling by mediating long-range interactions 
between distant enhancers and promoters (Rollins et al., 1999). Furthermore, NIPBL was 
reported to be involved in the loading of the cohesin complex onto chromatin by stimulating 
the ATP hydrolysis that determines the opening of the cohesin ring (Dorsett, 2004). 
The second component of the cohesin-loader complex MAU2 is characterized by the presence 
of TRP domains (Tetratricopeptide repeats) that are responsible for protein-protein interactions. 
Besides mediating the cohesin loading onto DNA in association with NIPBL, little is known 
about MAU2 functions (Watrin et al., 2006). 
PDS5 is also evolutionary conserved and contains HEAT repeats, similarly to other cohesin-
associated proteins (Neuwald and Hirano, 2000). Its function is to promote the generation of a 
cohesive state of the ring through the direct interaction with the structural elements SMC1A, 
SMC3 and RAD21 and the regulators ESCO1, sororin and WAPL (Tanaka et al., 2001; Dorsett 
et al., 2005; Losada et al., 2005; Losada and Hirano, 2005). Vertebrates present two different 
isoforms of PDS5, PDS5A and PDS5B, both involved in the regulation of the cohesin’ cycle. 
The depletion of PDS5 does not affect the binding of cohesin to the DNA, but prevents the 
establishment of cohesion (Tanaka et al., 2001; Losada and Hirano, 2005). 
Cohesin also interacts with a protein called WAPL (Wings-apart like) through RAD21 and 
STAG1/STAG2 (Kueng et al., 2006). The main role of WAPL is to mediate the removal of 
cohesin from chromosomes during prophase, thus playing an antagonist function compared to 
PDS5. In WAPL-depleted cells cohesin does not dissociate from chromosomes arms; as a 
consequence, metaphase chromosomes show low resolution of the sister chromatids (Kueng et 
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al., 2006). Conversely, the overexpression of WAPL was shown to cause premature separation 
of sister chromatids, thus driving tumorigenesis in mice (Oikawa et al., 2004). 
Sororin is another cohesin-associated protein that has been found only in vertebrate cells. As 
PDS5, Sororin is dispensable for the association of the cohesin complex with the DNA, but is 
needed for the establishment of cohesion. As point of fact, human cells that were depleted of 
Sororin display severe cohesion defects, despite the overall amount of chromatin-bound 
cohesin remains unchanged (Schmitz et al., 2007). Additionally, it has also been suggested that 
Sororin protects cohesin from a precocious dissociation from the DNA, possibly by inhibiting 
the activity of WAPL. This is in agreement with the finding that Sororin becomes dispensable 
for sister chromatid cohesion in the absence of WAPL (Nishiyama et al., 2010). Consequently, 
it can be assumed that Sororin plays a role both in cohesion establishment and maintenance 
(Diaz-Martinez et al., 2007). 
ESCO1/2, the human hortologues of the Saccharomyces cerevisiae Ctf7/Eco1, are also required 
for the establishment of a cohesive state (Ivanov et al., 2002). These genes encode for 
acetyltransferases whose human substrate is SMC3. It has been proved that depletion of 
ESCO1 or ESCO2 in different cell lines is responsible for massive cohesion defects (Unal et 
al., 2008; Zhang et al., 2008). Hence, ESCO1/2 are essential for the establishment of cohesion. 
As a proof, mutations in ESCO2 result in Roberts syndrome, a genetic disorder associated to a 
peculiar cytological phenotype characterized by heterochromatin repulsion of sister chromatids 
(OMIM #268300; Vega et al., 2005). 
After the separation of sister chromatids, SMC3 needs to be deacetylated in order to allow the 
proper dissolution of pro-cohesive elements and the recycling of cohesin for the next cycle. 
HDAC8 (OMIM #300269, Xq13.1) was recently identified as the vertebrate deacetylase for 
SMC3 (Deardorff et al., 2012b). Thus, the role of HDAC8 is indispensable for the 
establishment of a new functional cohesin complex. 
 
Table 2. Cohesin structural elements and regulatory proteins in different organisms (from Metha et al., 2013) 
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MODELS OF INTERACTION OF COHESIN WITH DNA 
Numerous models have been proposed in order to explain how the cohesin complex is able to 
hold sister chromatids together (Losada, 2007). These models can be classified into four 
categories: the embrace model, the two rings model, the bracelet model and the rod model 
(Fig.6). 
The embrace model (Fig.6a), also known as one ring model or topological model, seems to be 
the most plausible one; based on this theory, the tripartite structure formed by SMC1A, SMC3 
and RAD21 embraces the two DNA duplexes, that remain therefore entrapped into the cohesin 
ring following the closure of the ring determined by the binding of ATP. In the two ring model 
(Fig.6b), one single cohesin ring encircles one sister chromatid; the two chromatids are then 
hold together by direct or indirect interaction of the two cohesin complexes. Based on the 
bracelet model (Fig.6c), SMC heterodimers form multimeric filaments that entrap sister 
chromatids inside the oligomeric bracelet. The multiple heterodimers are connected to each 
other through RAD21. 
 
 
Figure 6. Models proposed to explain how the cohesin complex is able to mediate cohesion of sister chromatids during mitosis 
(from Mehta et al., 2012) 
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Lastly, for the fourth model (Fig.6d), a rod shaped structure of cohesin have been proposed. 
Transmission electron microscopy experiments in budding yeast have shown that cohesin 
present a rod shaped structure and that sister minichromosomes are able to interact at one end 
of the rod. Moreover, the width of the rod indicates that multiple cohesin complexes interact 
with each other along their arms in order to mediate cohesion.  
 
CELL CYCLE REGULATION BY COHESIN 
The activity of the cohesin complex is tightly regulated throughout the cell cycle in order to 
allow the proper dissociation of sister chromatids (Fig.7). Interactions with accessory proteins 
and post-translational modifications are responsible for this regulation. 
 
Figure 7. Schematic representation of the regulation of the cohesin complex throughout the cell cycle (from Zakari et al., 2015) 
 
The loading of cohesin onto chromatin 
In order to hold sister chromatids together, cohesin must bind to the DNA before its replication. 
In vertebrates, the loading of cohesin onto the DNA is performed during the telophase of the 
previous cell cycle by the protein complex NIPBL/MAU2 (Michaelis et al., 1997; Losada et al., 
2000; Haering et al., 2004). No sequence specificity has been observed for the loading of 
cohesin onto chromosomes: its initial positions and its permanent locations vary among 
different organisms (Michaelis et al., 1997; Losada et al., 2000; Haering et al., 2004).   
Once cohesin is bound to the DNA, the cohesin loader NIPBL/MAU2 becomes dispensable 
(Ciosk et al., 2000). This suggests that this complex is responsible for the physical association 
between cohesin and chromosomes, but it does not have any role in the assembly of the cohesin 
complex starting from the single subunits or in the establishment and maintenance of cohesion. 
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Therefore, it can be speculated that a preassembled cohesin ring gets loaded onto chromatin. 
For this to be possible, the cohesin complex should be opened in order to be able to embrace 
sister chromatids. In this context, evidence suggests that chromosomes enter the cohesin ring 
through its hinge domain (Gruber et al., 2006). The energy required for this opening is given by 
the mechanism through which the hinge bends towards the ATPase heads; in this way the head 
domains become able to provide the energy for the opening of the ring through the hydrolysis 
of ATP (McIntyre et al., 2007). 
 
Establishment of cohesion 
The association of the cohesin complex with chromosomes is not enough to keep sister 
chromatids together. For this purpose, DNA-associated cohesin must achieve a “pairing 
competent state”, a process known as establishment of cohesion. For this attainment, the key 
player are the conserved proteins ESCO1/ESCO2, that are responsible for the acetylation of 
SMC3 (Ivanov et al., 2002). Cell cycle dependent studies in yeasts and humans demonstrated 
that SMC3 is not acetylated during the G1 phase, but its level of acetylation rises during S 
phase. Accordingly, the essential function of ESCO1/ESCO2 in generating cohesion is 
confined to the S phase. Hence, these acetyltransferases are only required for the establishment 
of a cohesive state concomitant to replication, but are unable to mediate the maintaining of 
cohesion. Nevertheless, the “pairing competent state” should be preserved until the beginning 
of anaphase. In this context, PDS5 plays a very important role because it ensures cohesion 
throughout the G2 phase and during the transition between G2 and M. In point of fact, as 
previously mentioned, PDS5 interacts with other cohesin-associated proteins like Sororin and 
WAPL. It has been demonstrated that the association of PDS5 with Sororin maintains a 
cohesive state, while a non-cohesive state is promoted when PDS5 interacts with WAPL 
(Sutani et al., 2009; Nishiyama et al., 2010). In other words, Sororin and WAPL compete for 
the binding with PDS5 in order to mediate the maintenance or the disruption of cohesion, 
respectively.  
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The removal of cohesin from chromatin 
The dissociation of cohesin from the DNA is mediated by two different pathways based on the 
position of the complex along chromosomes: cohesins localized on chromosomes arms are 
removed during prophase whereas cohesins bound to pericentromeric and centromeric regions 
are preserved until the onset of anaphase (Waizenegger et al., 2000). The dissociation of 
cohesin during prophase is mediated by the two mitotic kinases Polo-like kinase 1 (Plk1) and 
Aurora B, which are responsible for the phosphorylation of RAD21 and of the STAG subunits, 
thus triggering the opening of the cohesin ring. During this phase, centromeric cohesins are 
protected from the activity of the kinases by the protein shugoshin and the phosphatase PP2A: 
Shugoshin directly interacts with PP2A and recruits it at the centromeres, thus neutralizing the 
activity of the kinases (Giménez-Abián et al., 2004; McNairn e Gerton, 2008). It is worth to be 
noted that this prophase pathway determines the dissociation of cohesin from chromosomes 
without cleaving the single subunits, thus sparing the complex from the destruction. As a result, 
cells exit mitosis with almost an unchanged pool of cohesin complexes available for a new 
loading immediately after the generation of the nuclear envelope. This is of high physiological 
significance because it has been demonstrated that cohesin plays an important role in gene 
expression regulation during the G1 phase, and so before the establishment of cohesion (Wendt 
et al., 2008). 
The dissociation of cohesin during anaphase and the complete dissolution of the complex are 
mediated by three elements: securin, separase and the Anaphase-Promoting Complex (APC). 
Before the onset of anaphase, the proteolytic activity of the separase is inhibited because of its 
physical association with securin. Once the sister kinetochores becomes bioriented on mitotic 
spindles, the anaphase checkpoint is inactivated, thus determining the activation of APC. 
Activated-APC mediates the ubiquitin-dependent degradation of the securin. The separase is 
now free to cleave RAD21: the cohesin complex dissociates from the DNA and sister 
chromatids can now reach the opposite poles of the cell (Ciosk et al., 1998; Uhlmann et al, 
1999). 
The deacetylation of SMC3 performed by HDAC8 is then essential in both prophase and 
anaphase pathways in order to allow the proper dissolution of the cohesin complex and the 
recycling of the subunits for the next cell cycle (Deardorff et al., 2012b). 
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COHESIN´S FUNCTIONS 
In the last decade, extensive research on the function and structure of cohesins has revealed that 
the complex is involved in many other cellular processes apart from mediating sister chromatid 
cohesion. These additional functions include transcriptional regulation, chromatin remodeling, 
DNA double-strand breaks (DSB) repair, chromosomes condensation and morphogenesis and 
centrosome-related activities (Fig.8; Uhlmann, 2008; Sjögren and Ström, 2010; Cuylen and 
Hearing, 2011; Dorsett, 2011; Feeney et al., 2012; Sofueva and Hadjur, 2012). It is worth to be 
noted that sister chromatid cohesion per se might be directly involved in these non-canonical 
roles of the cohesin complex.  
 
 
Figure 8. Schematic representation of the non-canonical functions of cohesins. (a) DSB repair is mediated by cohesin binding 
to the break site. In response to a DSB, cohesion is also re-enforced genome-wide. (b) Cohesin regulates gene expression 
through gene looping. (c) Cohesin promotes chromosome condensation (from Zakari et al., 2015) 
 
Transcriptional regulation 
The earliest evidence of the role of cohesin as a key regulator of transcription came with studies 
on Saccharomyces cerevisiae and Drosophila melanogaster (Donze et al., 1999; Rollins et al., 
1999).  
In budding yeast cohesin was found to play an important role at the silent mating type locus, 
where it acts as boundary element in order to restrict the spreading of transcriptional silencing 
(Donze et al., 1999). In fission yeast the cohesin complex was instead shown to regulate 
transcriptional termination (Gullerova and Proudfoot, 2008). 
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In Drosophila melanogaster, both Nipped-B and cohesin were found to be involved in gene 
expression regulation. Specifically, Nipped-B activates the transcription of the homeobox genes 
Cut and Ultrabithorax by mediating the long-range interaction of the promoters with the 
respective enhancers (Rollins et al., 1999). On the other hand, in postmitotic mushroom body γ-
neurons, cohesin is required for the transcriptional activation of the Ecdyson steiroid hormone 
Receptor (EcR), a factor indispensable for axon pruning (Schuldiner et al., 2008). Recent 
studies in Drosophila melanogaster have also proved that cohesin selectively binds to genes on 
which the RNA polymerase II is paused just downstream of the transcription start site. 
Therefore, it is presumable that cohesin is involved in the regulation of the transition of the 
polymerase between a paused state and an active transcription elongation state (Fay et al., 
2011). 
In the following years, the role of NIPBL and cohesin in the transcriptional regulation was 
demonstrated also in other model organisms. In addition, even translation has been proved to be 
influenced by cohesin, thought indirectly. In point of fact, cohesin was reported to augment the 
translational capacity of cells by increasing the level of transcription of rRNA in budding yeast 
and humans (Bose et al., 2012). 
Nevertheless, the mechanisms by which cohesin mediates the regulation of gene expression are 
still not fully understood and vary among different organisms. For instance, in Drosophila 
melanogaster cohesin accumulates together with Nipped-B at the transcriptional start sites of 
active genes (Misulovin et al., 2008). Instead, in humans, cohesin co-localizes with both 
NIPBL and the CCCTC-binding factor (CTCF), a well-known insulator (Wendt et al., 2008).  
The way cohesin fulfills its role in the regulation of gene expression is linked with the 
mechanism through which it mediates sister chromatid cohesion. As previously mentioned, 
cohesin is able to hold sister chromatids together by entrapping them in a ring-like structure. In 
the same way, the cohesin ring might be able to bring together non-contiguous genomic regions 
through the generation of DNA loops. Long-range interactions between distant genomic 
regions obtained thanks to DNA looping might therefore be the key event through which 
cohesin is able to influence gene expression (Rollins et al., 1999). Notably, cohesin can induce 
both transcriptional activation or repression depending on which elements are brought in close 
proximity and on whether an enhancer or a silencer is sequestered into the loop.  
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Chromatin remodeling 
Cohesin was also shown to interact with chromatin remodeling complexes. In particular, ChIP 
experiments showed a direct interaction between the cohesin subunit RAD21 and the ATPase 
SNF2h of a chromatin remodeling complex. This cooperation is needed to modify histone tails 
in order to regulate the accessibility of the DNA (Hakimi et al., 2002). In addition, NIPBL was 
found to interact with the deacetylases HDAC1 and HDAC3. The minimal region of interaction 
in NIPBL is confined to 163 aa at the C-terminal of the protein (1838-2000). Mutations in this 
region determine an impairment of the ability of NIPBL to bind HDAC1 and HDAC3 (Jahnke 
et al., 2008). It might be assumed that the previously reported interactions are needed to 
promote the binding of cohesin to the target DNA following the modification of the chromatin 
structure.  
 
DNA repair 
Studies on Saccharomyces pombe provided the first evidence for the involvement of cohesin in 
DNA repair, and so in the maintenance of genomic stability. In fact, in fission yeast, cohesin 
mutants are sensitive to γ-irradiation due to a defect in the repairing of DSBs (Birkenbihl and 
Subramani, 1992). Since then, the role of cohesin in DSBs repair was confirmed in different 
organisms (Sjörgen and Nasmyth, 2001; Musio et al., 2005; Cortés-Ledesma and Aguilera, 
2006). 
At the beginning, the repair of DSBs was thought to depend on the cohesin complexes already 
bound to the DNA during the S phase. Conversely, it has been demonstrated that, in the 
presence of DNA damage, cohesin can be loaded onto DNA and generate cohesion even in the 
post-replicative phase as a result of the increased activity of the cohesin loader and of the 
acetylases ESCO1/2 (Ström et al., 2004). It is worth to be noted that this damage-induced 
cohesion is generated globally on all chromosomes and not only at the site of damage (Unal et 
al., 2007). In this context, the job of cohesin is to bring sister chromatids together, so that the 
wild type chromatid can be used as template for homologous recombination in order to mediate 
the repair of the strand carrying the DSB.  
In budding yeast, epigenetic marks were analyzed to understand the targeting of the cohesin 
complex at the damage site. It has been demonstrated that the main epigenetic mark for this 
purpose is the phosphorylation of histone H2AX by the checkpoint kinases Mec1 and Tel1 at 
least 60 kb from the DSB site (Unal et al., 2004). In addition, also the MRX complex 
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(Mre11/Rad50/Xrs2) is able to promote the assembly of cohesin at breakage sites (Fig.9; Unal 
et al., 2004).  
In humans, cohesin has also been found to play an important role for the activation of the intra 
S phase and G2-M checkpoints following the generation of a DSB (Kim et al., 2002; Yazdi et 
al., 2002; Luo et al., 2008; Watrin and Peters, 2009).  
 
 
Figure 9. Schematic representation of DNA repair mediated by cohesin in yeast: upon a DSB, cohesin loading is directed to the 
region of the damage following the phosphorylation of H2AX and binding of MRX to the break site.The inhibition of Eco1 is 
then removed, thus allowing the generation of a cohesive-state (from Onn et al., 2008) 
 
 
Interestingly, it has been shown in budding yeast that a reduction of more than 80% of the 
cohesin’ activity is associated to normal cohesion, but leads to defects in DNA repair and 
chromosome condensation (Ellermeier and Smith, 2005). These data underlines the importance 
of cohesin stoichiometry for the regulation of cellular processes different from sister chromatid 
cohesion, that hence appear to be highly dosage-sensitive. Accordingly, a small amount of 
weakly bound cohesin seems to be sufficient to mediate sister chromatid cohesion whereas 
non-canonical functions depend upon high levels of strongly bound cohesin. This hypothesis is 
further confirmed by the absence of cohesion defects in cell lines of CdLS patients (Castronovo 
et al. 2009; Dorsett and Krantz, 2009). 
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Chromosomes condensation 
Chromosome morphogenesis is an essential step for the correct distribution of the genetic 
material during mitosis and depend on DNA condensation. Chromosome compaction is mainly 
mediated by condensins, a highly conserved cohesin-like complex containing SMC proteins 
(Lavoie et al., 2002).  
In fission yeast and budding yeast changes in the level of cohesin were found to be responsible 
for a hypo- or hyper-condensation of chromosomes, possibly due to altered targeting of 
condensins to the chromosomes (Hartman et al., 2000; Losada et al., 2002). These results 
suggest that cohesin might be involved in the control of the localization of condensins on 
chromosomes. This hypothesis was proved in 2004, when a study in budding yeast 
demonstrated that chromosome compaction occurs in two steps, and that the first step depends 
on cohesin (Lavoie et al., 2004). A further confirmation of this theory was given by Chromatin 
Immunoprecipitation (ChIP) experiments on budding yeast, which proved that occupancy sites 
of condensins overlap with those of the cohesin loader complex, thus implying a co-localization 
of condensins with cohesin (D’Ambrosio et al., 2008). Nevertheless, the mechanisms of 
interaction between condensin and cohesin are still poorly understood.  
 
Centrosome-related functions 
Several studies have demonstrated a role of cohesin in the duplication of the microtubule-
organizing centers, also known as centrosomes. The first evidence came in 2006, when it was 
shown that the separase is needed not only for the cleavage of the cohesin ring, but also for 
centriole disengagement and centrosome duplication (Tsou and Stearns, 2006). In the following 
years cohesin subunits were also identified at the spindle pole and centrosomes (Wong and 
Blobel, 2008; Kong et al., 2009). Moreover, depletion of RAD21 in HeLa cells was associated 
with a premature separation of paired centrioles, and also shugoshin was shown to be required 
for the protection of the cohesion between centrioles (Wang et al., 2008; Nakamura et al., 
2009). Lastly, the premature activation of the separase or the depletion of the shugoshin were 
found to cause both premature sister chromatid separation and premature centriole 
disengagement (Schockel et al., 2011). These data suggest that the chromosome and 
centrosome cycles might be coordinated with each other as a result of the dual role played by 
cohesin (Schockel et al., 2011). 
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THE CdLS-GENES: STATE OF ART 
To date, mutations in five different cohesin-related genes have been described as a genetic 
cause of CdLS, namely NIPBL, SMC1A, SMC3, RAD21 and HDAC8 (Krantz et al., 2004; 
Tonkin et al., 2004; Musio et al., 2006; Deardorff et al., 2007; Deardorff et al., 2012a; 
Deardorff et al., 2012b). 
 
NIPBL 
The cohesin loader NIPBL is the “major gene” of the syndrome: mutations can be identified in 
more than half of CdLS cases (Borck et al., 2004; Gillis et al., 2004; Selicorni et al., 2007). 
To date, more than 300 variants affecting NIPBL have been identified in CdLS patients. Most 
of the mutations arise de novo, though also a small number of familial cases has been 
described. All types of variants have been reported so far, including out-of-frame deletions or 
insertions, missense, nonsense, and splicing mutations. Large scale genomic alterations have 
also been identified, but with a lower frequency. Among point mutations, out-of-frame 
deletions resulting in premature termination codons are the most frequent (28%), followed by 
missense substitutions (21%), nonsense and splicing mutations (17% each), duplications (14%), 
insertions (1,5%) and indels (1,5%) (Mannini et al., 2013). 
Mutations in NIPBL are scattered along the entire gene without apparent hotspots. 
Nevertheless, a large number of variants has been identified in exons 10 and 47 because of their 
length (Oliveira et al., 2010). Out-of-frame deletions, nonsense and splicing mutations, all 
presumably leading to a truncated and nonfunctional NIPBL protein, are associated with a more 
typical and severe phenotype characterized by profound developmental and cognitive delay 
with absence of speech, severe pre- and postnatal growth retardation, typical facial 
dysmorphisms and high frequency of limb reductions or malformations. Conversely, missense 
substitutions are generally associated with a milder phenotype; in point of fact, limb anomalies 
are rarely observed and cognitive impairment, growth retardation and developmental delay are 
less severe (Fig.10 A-H) (Selicorni et al. 2007). Patients with large scale genomic 
rearrangements present instead with a phenotype that correlates with the size of the region and 
with the number of exons involved: patients with deletions spanning beyond NIPBL sequence 
or involving large portions of the gene are associated with severe growth and cognitive delay 
and with upper limb malformations. Contrariwise, deletions of one or few exons frequently 
result in a milder phenotype (Russo et al., 2012; Gervasini et al., 2013; Mannini et al., 2013).  
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The severity of the phenotype also depends on the functional domain involved. Indeed, variants 
affecting the HEAT repeats were shown to be associated with a more severe phenotype, 
putatively based on the modified ability of NIPBL to interact with other proteins (Mannini et 
al., 2013). Nevertheless, CdLS unrelated patients sharing the same mutation might present with 
different clinical features. This observation points out that, beside the effects of the mutations 
themselves, other genetic or environmental factors may play an important role in determining 
the phenotypcal expression (Mannini et al., 2013). 
Cell lines of CdLS patients carrying mutations in NIPBL show a reduction of the NIPBL 
transcript of 30%, thus suggesting that the pathogenic mechanism is likely to be linked to 
haploinsufficiency (Dorsett and Krantz, 2009). 
Furthermore, mosaicism was recently proved to play a very important role in association with 
NIPBL: more than 20% of patients who were reported to be mutation-negative on DNA 
extracted from blood were then found to carry a mutation in NIPBL on DNA isolated from 
buccal mucosa or fibroblasts (Husiman et al., 2012; Baquero-Montoya et al., 2014). No 
significant differences were identified between the phenotype of patients with somatic 
mosaicism o with a constitutional mutations, thus excluding the possibility to discern in 
advance the two categories of patients (Huisman et al., 2013). Three mechanisms have been 
proposed in order to explain the onset of mosaicism, namely somatic mutation after 
fertilization, negative selection of mutant lymphocytes or loss of the mutation due to reversion. 
Though, negative selection seems to be the most likely explanation, since no remarkable 
phenotypical differences were observed between patients with or without mosaicism, and since 
mutation reversion is mainly associated to skin disorders (Huisman et al., 2013). 
 
SMC1A 
Mutations in SMC1A have been identified in about 5% of CdLS patients. So far, 44 CdLS 
individuals harboring 29 different mutations have been described (Borck et al., 2007; Deardorff 
et al., 2007, Liu et al., 2009; Limongelli et al., 2010; Mannini et al., 2010; Pié et al., 2010; 
Hoppman-Chaney et al., 2011).  
Mutations were identified throughout the entire protein with the exception of the highly 
conserved hinge domain. Moreover, only missense mutations or in frame-deletions have been 
reported in CdLS patients with mutations in SMC1A. The observation that nonsense mutations 
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or out-of-frame deletions have never been reported points out that they might lead to a different 
phenotype or they are likely not tolerated (Mannini et al., 2013).  
In agreement with the X-linked dominant transmission, females present with a very broad 
spectrum of phenotypical features ranging from very mild to very severe. Conversely, males 
show a more homogeneous and severe clinical presentation. In general, patients harboring 
mutations in SMC1A are characterized by a milder phenotype compared to those who carry 
mutations in NIPBL: in point of fact SMC1A-patients present with a tendency towards normal 
auxological parameters, a mild to moderate cognitive impairment and less remarkable facial 
features (Fig.10 M-N; Mannini et al., 2013). 
Interestingly, SMC1A localizes at Xp11.22, a region of the X-chromosome that partially 
escapes X-inactivation in humans. The rate of escaping of the allele on the inactive X-
chromosome ranges from 15% to 30% (Carrell and Willard, 2005). It is worth to be noted that 
healthy females were shown to express SMC1A at higher levels compared to healthy males (Liu 
et al., 2009). Moreover, patients with mutations in SMC1A were shown to express equal levels 
of transcript and protein compared to controls (Revenkova et al., 2009). Furthermore, mutations 
in SMC1A do not prevent the incorporation of the mutant protein into the cohesin complex and 
SMC1A-mutated heterodimers show a higher affinity for chromatin than normal dimers 
(Revenkova et al., 2009; Gimigliano et al., 2012). All together, these findings suggest that a 
dominant negative effect might be the pathogenic mechanism associated to mutations in 
SMC1A. 
 
SMC3 
To date, only one mutation in SMC3 has been described in a single CdLS patient (Fig.10 Q-U). 
The mutation is a small in-frame deletion of three nucleotides (c.1464-1466delAGA) that 
results in the deletion of a single amino acid (p.E488del) and localizes in the coiled-coil region 
of the SMC3 protein (Deardorff et al., 2007). The patient showed pre- and postnatal growth 
retardation and moderate cognitive and developmental delay. He presented with GERD, but did 
not show any other major malformation (Deardorff et al., 2007). The low frequency of 
mutations in SMC3 indicates that this gene might play important roles beyond cohesion 
(Mannini et al., 2013). In agreement with this hypothesis, SMC3 acetylation was found to 
control the fork processivity in human cells (Zhang et al., 2008). 
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RAD21 
Mutations in RAD21 were identified in eight CdLS patients (Deardorff et al., 2012a; Minor et 
al., 2014). Cell lines expressing mutant-RAD21 showed significantly lower cell survival and 
elevated levels of chromosomal structural rearrangements compared to normal cells after 
irradiation (Deardorff et al., 2012a). 
Mutations in this gene are responsible for a human cohesinopathy that overlaps with CdLS and 
is mainly characterized by short stature, minor skeletal anomalies and facial features including 
synophrys, micrognathia and brachydactyly (Fig.10 O-P). Interestingly, individuals with 
mutations in RAD21 present with a significantly milder cognitive impairment (Deardorff et al., 
2012a). 
 
HDAC8 
To date, mutations in HDAC8 have been reported in about 5% of patients (Deardorff et al., 
2012b; Kaiser et al., 2014; Feng et al., 2014; Yuan et al., 2015). All types of mutations have 
been identified so far; nevertheless, no correlations between the mutation and the clinical 
phenotype could be deduced. Similarly to NIPBL haploinsufficiency, mutations in HDAC8 
were found to cause only a modest reduction of the levels of the transcript (Deardorff et al., 
2012b). 
Patients with mutations in HDAC8 tend to present with a phenotype that partially overlaps with 
CdLS but that is also characterized by atypical features including the late closure of the anterior 
fontanelle, a broad or bulbous nasal tip, hypertelorism, hooding of the eyelids, mosaic skin 
pigmentation and teeth anomalies (Fig.10 I-L; Kaiser et al., 2014). Importantly, HDAC8 is also 
an X-linked gene. Accordingly, as for SMC1A, males show a homogeneous and more severe 
clinical presentation while females, who represents the vast majority of HDAC8-mutated CdLS 
patients, present with a broad range of phenotypes also based on the level of X-inactivation. In 
point of fact, most of the female patients show complete skewing towards the wild type allele 
in blood, thus indicating a strong selection against the mutation (Deardorff et al., 2012b; Kaiser 
et al., 2014).  
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Figure 10. Phenotype of patients carrying mutations in the five cohesin-associated genes responsible for CdLS. (A-D) Female 
patient carrying a truncating mutation in NIPBL. (E-H) Male patient harboring a missense mutation in NIPBL. (I-L) Female 
patient with an in-frame deletion in HDAC8. (M-N) Female patient with a missense mutation in SMC1A. (O-P) Male patient 
with a deletion of RAD21. (Q-U) Male patient carrying the in-frame deletion in SMC3 (from Mannini et al., 2013). 
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MISSING HERITABILITY 
The five genes NIPBL, SMC1A, SMC3, RAD21, and HDAC8, also taking into account the role 
of mosaicism, are responsible for about 70% of CdLS cases. Thus, the molecular cause 
underlying the syndrome is still not known in about 30% of CdLS patients. 
A lot of effort has been invested in order to try to cover this missing heritability. It can be 
speculated that the remaining cases could be explained by the presence of undetectable 
mutations in the known CdLS genes as well as of mutations affecting genes with a function 
similar to the one of cohesin. The employment of high-throughput techniques such as next 
generation sequencing or CGH-array could help to shed light on this phenomenon. 
 
DIFFERENTIAL DIAGNOSIS 
Part of the missing heritability might also be linked to sometimes miscarried diagnosis due to 
phenotypical overlap between CdLS and other syndromes. The main syndromes that represent 
a differential diagnosis to CdLS are the following. 
 
KBG SYNDROME 
KBG syndrome (OMIM #148050) is a rare genetic disorder characterized by postnatal growth 
retardation, developmental delay, cognitive impairment, skeletal anomalies, brachycephaly and 
a typical round facies displaying broad and arched eyebrows, hypertelorism, a broad or bulbous 
nasal tip and a long philtrum (Hermann et al., 1975; Ockeloen et al., 2014). The hallmark of the 
syndrome is the presence of dental anomalies, a feature that is instead not common for CdLS 
(Ockeloen et al., 2014). 
KBG syndrome is caused by loss-of-function mutations in the ANKRD11 gene (OMIM 
#611192, 16q24.3), encoding for a transcriptional repressor also known as ankyrin repeat-
containing protein 11 (Sirmaci et al., 2011). ANKRD11 contains one activation domain that is 
able to stimulate transcription, two repression domains and five ankyrin repeats needed to 
mediate protein-protein interactions (Zhang et al., 2007). The protein is able to inhibit 
transcriptional activation by interacting with the deacetylases HDAC3, HDAC4 and HDAC5 
and by recruiting them to target genes of nuclear receptors, thus inhibiting their transcription 
(Sirmaci et al., 2011). ANKRD11 was also found to localize within the nuclei of neurons and to 
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accumulate in distinct inclusions after their depolarization. This data suggests that ANKRD11 
also plays a role in neural plasticity (Sirmaci et al., 2011). 
 
COFFIN-SIRIS SYNDROME 
Coffin-Siris syndrome (CSS, OMIM #135900) is a rare multisystem developmental disorder 
characterized by a coarse facies and typical facial features including thick and arched 
eyebrows, long eyelashes, a broad nasal bridge and nasal tip, a wide mouth and thick and 
everted lips (Schrier et al., 2012). CSS patients also present with short stature, cognitive 
impairment, psychomotor delay, feeding difficulties and hypoplasia or aplasia of the fifth 
fingernail or digit. Additionally, they can display hirsutism, microcephaly and sparse scalp hair 
(Schrier et al., 2012). 
Mutations in different subunits of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex 
were found to be associated with the syndrome (Santen et al., 2012; Tsurusaki et al., 2012). 
 
Figure 11. Schematic representation of the SWI/SNF complex, that is highly conserved during evolution. The names of the 
main subunitsare indicated for different organisms (mouse and humans) 
 
The SWI/SNF complex (Fig.11) is a family of highly conserved chromatin remodelers. 
Though, the subunits of the complex can vary among different organisms. In addition, in 
humans, the numerous subunits are encoded by more than one gene, so that different 
combinatorial assemblies of the complex are possible. The various combinations are then 
tightly regulated during cell development and differentiation (Kosho et al., 2014). Typically, a 
human SWI/SNF complex contains a single ATPase, represented by SMARCA2 (OMIM 
#600014, 9p24.3) or SMARCA4 (OMIM #603254, 19p13.2), some core subunits including 
SMARCB1 (OMIM #601607, 22q11.23), SMARCC1 and SMARCC2 and some accessory 
subunits, the most important of which are ARID1A (OMIM #603024, 1p36.11), ARID1B 
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(OMIM #614556, 6q25.3) and SMARCE1 (OMIM #603111, 17q21.2). To date, CSS-causing 
mutations have been identified in ARID1B, ARID1A, SMARCA2, SMARCB1 and SMARCA4, 
thus indicating genetic heterogeneity (Santen et al., 2012; Tsurusaki et al., 2012). In addition, 
mutations in the SWI/SNF-associated protein PHF6 (OMIM #300414, Xq26.2) have also been 
proven to cause CSS (Wieczorek et al., 2013). ARID1B represents the major gene of the 
syndrome and loss-of-function mutations can be identified in more than 70% of CSS cases 
(Wieczorek et al., 2013). All the ARID1B-mutations so far identified are truncating and are 
predicted to determine haploinsufficiency (Wieczorek et al., 2013). 
As cohesin, the SWI/SNF complex is involved in various cellular processes including ATP-
dependent chromatin remodeling, gene expression regulation, cell cycle regulation and 
differentiation. Accordingly, mutations in subunits of the SWI/SNF complex have been 
identified in different types of cancer (Wieczorek et al., 2013). 
 
WIEDEMANN-STEINER SYNDROME 
Wiedemann-Steiner syndrome (WDSTS, OMIM # 605130) is a heterogeneous disorder also 
known as “hairy elbows syndrome” due to a peculiar and frequently observed excessive hair 
growth around the proximal third of the forearm and the distal third of the upper arm. The 
syndrome is also characterized by short stature, intellectual disability and distinctive facial 
features including thick eyebrows, long eyelashes, vertically narrowed and downslanted 
palpebral fissures, broad nasal bridge and nasal tip (Wiedemann et al., 1989; Steiner and 
Marques, 2000). 
Mutations in the KMT2A gene (OMIM #159555, 11q23.3) are responsible for WDSTS (Jones 
et al., 2012). KMT2A is a lysine-specific methyltransferase that plays an essential role in the 
regulation of gene expression during hematopoiesis and early development. The protein is 
highly conserved and consists in multiple functional domains, the most important of which is 
the SET domain, which is responsible for the enzymatic activity (Jones et al., 2012).  
Multiple chromosomal translocations involving KMT2A are described in association with acute 
lymphoid leukemias and acute myeloid leukemias (Nilson et al., 1996; Taki et al., 1996). 
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RUBINSTEIN-TAYBI SYNDROME 
Rubinstein-Taybi syndrome (RSTS, OMIM #180849) is characterized by postnatal growth 
retardation, intellectual disability, broad and angulated thumbs and halluces and typical facial 
features that include downslanted palpebral fissures, a beaked nose with the columella 
extending below the nares, grimacing smile, highly arched palate and Talon cusps (Rubinstein 
and Taybi, 1963; Hennekam, 2006).  
To date, mutations in two different genes have been associated with RSTS. The major gene of 
the syndrome is CREBBP (OMIM #600140, 16p13.3). CREBBP mutations are responsible for 
more than 50% of RSTS cases (Bartsch et al., 2005; Bentivegna et al., 2006; Spena et al., 
2014). The second gene EP300 (OMIM #602700, 22q13.2) accounts for about 8% of RTS 
cases (Roelfsema et al., 2005; Negri et al., 2015). Both CREBBP and EP300 are transcriptional 
co-activators involved in the regulation of the expression of various signaling pathways. The 
two genes encode for homologous proteins highly conserved during evolution that play an 
important role as acetyltransferases (Roelfsema et al., 2005). Interestingly, a patient with a 
clinical diagnosis of CdLS was found to carry a mutation in the EP300 gene in 2013 (Fig.12; 
Woods et al., 2013). 
 
 
Figure 12. Facial appearance of the CdLS patient carrying a mutation in the EP300 gene. To be noted the presence of thick 
and arched eyebrows with synophrys, long eyelashes, depressed nasal bridge with anteverted nares and smooth philtrum (from 
Woods et al., 2013) 
 
The patient, a Caucasian male born to healthy parents, presented with typical CdLS facial 
features including microbrachycephaly, thick and arched eyebrows with synophrys, ptosis, long 
eyelashes, depressed nasal bridge with anteverted nares, smooth and long philtrum, and thin 
lips. He also displayed growth retardation, cognitive impairment, developmental delay, 
hirsutism, respiratory distress, supraventricular tachycardia, hypospadias, cryptorchidism, 
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increased bifrontal subarachnoid spaces and a severe, progressive and rigid scoliosis. He died at 
the age of 5 years 3 months because of severe bronchopneumonia (Woods et al., 2013). 
The finding of a mutation in EP300 in a patient with a clinical diagnosis of CdLS is of 
particular interest and highlights the already suggested phenotypical overlap between CdLS and 
RSTS (Gorlin et al., 2001). A functional link between EP300 and the cohesin-associated genes 
has also been established. In point of fact, both EP300 and HDAC8 are key regulators of the 
transcriptional activity of p53 (Yan et al., 2013). In addition, EP300 and NIPBL have been 
shown to localize at putative enhancer regions in different cell types and were recently ranked 
as top enhancer signatures (Chen et al., 2012). It cannot be excluded that EP300 and the 
cohesin-associated genes are involved in the regulation of other common pathways, thus 
explaining the phenotypical overlap between the two syndromes.  
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AIM OF THE PRESENT WORK 
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CdLS is a heterogeneous disease characterized by clinical and genetic heterogeneity. Mutations 
in five genes have been so far identified as a genetic cause of CdLS, namely NIPBL, SMC1A, 
SMC3, RAD21 and HDAC8. Nevertheless, the impact each gene exerts on the syndrome has yet 
to be defined. In addition, mutations in the five genes are all together responsible for about 70% 
of CdLS cases. Hence, a molecular diagnosis is still not available for about 30% of CdLS 
patients. 
 
The present work originates from an international cooperation that involves different countries 
and is divided into the following section: 
 Definition of the mutational frequency of each CdLS-associated gene with particular 
attention to the role played by mosaicism. The assessment of the genotype-phenotype 
correlation is also of utmost importance for the definition of the most appropriate 
molecular testing in the presence of a diagnosis of CdLS 
 Investigation of the peculiar pattern of expression of SMC1A in healthy controls and in 
the CdLS population. In point of fact, this gene localizes on a region of the X 
chromosome that partially escapes X-inactivation. Therefore, the study of the overall 
and allele-specific expression of this gene could shed light on the pathogenic 
mechanisms underlying the syndrome in the presence of mutations in SMC1A 
 Identification of new causative genes by the use of next generation sequencing 
techniques. In this context, it can be speculated that genes encoding for proteins 
functionally associated with cohesin or with chromatin-related activity might be 
responsible for CdLS-overlapping phenotypes. Both targeted gene panel or genome-
wide approaches can be used for this purpose 
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MATERIALS AND METHODS 
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PATIENTS 
The patients herein described were recruited thanks to a large international cooperation that 
includes Italy, Spain, Germany, Sweden, Poland and the United States.  
All procedures involving human participants were performed in accordance with the ethical 
standards of the respective national research committees. Informed consent was obtained from 
all individuals participants included in this study. An additional consent was obtained for the 
publication of photographic material comprising patients. 
All children underwent complete physical and dysmorphologic evaluation by their referring 
clinical geneticists, who assigned a diagnosis of CdLS to most of the patients. Patients with an 
uncertain diagnosis but presenting CdLS-overlapping features were also included in this study. 
Patients’ DNA was analyzed through different techniques including Sanger sequencing and 
next generation sequencing approaches in order to identify the causative mutations. 
 
 
CELL CULTURE ESTABLISHMENT 
Cell cultures were generated from lymphoblasts or fibroblasts.  
Lymphoblastoid cell lines (LCLs) were established in collaboration with the Galliera Genetic 
Bank of the Galliera Hospital through Epstein-Barr virus transformation. LCLs were cultured 
in RPMI 1640 medium supplemented with 20% Fetal Bovine Serum (FBS) and 1% Antibiotics. 
Cells were grown at 37°C with 5% CO2. 
Skin biopsies were used to establish fibroblasts cell lines, which were grown in DMEM 
supplemented with 10% FBS and 1% Antibiotics at 37°C with 5% CO2. 
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DNA ISOLATION 
Genomic DNA was isolated from blood, LCLs, fibroblasts, buccal mucosa and urine. 
 
DNA ISOLATION FROM BLOOD, LCLs AND FIBROBLASTS 
DNA extraction from blood, LCLs and fibroblasts was performed with the QIAamp® DNA 
blood Mini Kit (Qiagen, Hilden, Germany), which enables rapid and efficient purification of 
high quality genomic DNA from a diverse variety of sample materials for a broad range of 
downstream applications. The isolation was performed according to the manufacturer’s 
instruction starting from 200 µl of whole blood or 5x106 cells. 
 
DNA ISOLATION FROM URINE 
Genomic DNA was isolated from 50 ml of urine.  
Cells were sedimented by centrifuging at 5000 rpm for 20 minutes at 4°C. The pellet was 
resuspended in 1 ml TNE buffer (10 mM Tris pH 8, 1 mM EDTA pH 8, 100 mM NaCl) and 
transferred to a 1,5 ml Eppendorf tube. Cells were then centrifuged again at 3000 rpm for 10 
minutes at 4°C and the pellet resuspended in 400 µl TNE plus (10 mM Tris pH 8, 1 mM EDTA 
pH 8, 100 mM NaCl, 1% SDS, 100 µg/ml Proteinase K). The resulting solution was incubated 
overnight in a thermo-shaker at 56°C and 500 rpm.  
The day after, 200 µl Phenol and 200 µl Clorophorm were added to the resuspension, which 
was then vortexed and incubated at room temperature for 10 minutes. After the incubation, a 
centrifugation at room temperature at 10000 rpm for 10 minutes was performed in order to let 
the different phases separate. 
The DNA contained in the supernatant was precipitated with 40 µl of 3M Sodium Acetate and 
1 ml of 100% Isopropanol (centrifugation at 14000 for 30 minutes at 4°C) and subsequently 
washed with 500 µl of 70% Ethanol (centrifugation at 14000 rpm for 5 minutes at 4°C).  
The purified DNA was dried in a speed vacuum and resuspended in 30 µl of distilled water. 
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DNA ISOLATION FROM BUCCAL MUCOSA 
Isolation of genomic DNA from buccal mucosa was performed with the MasterAmp™ Buccal 
Swab Kit (Epicentre, Cambridge, UK) according to the manufacturer’s instructions.  
The resulting DNA was precipitated with 1/10 volume of 3M Sodium Acetate and two volumes 
of Ethanol 100% by centrifuging at 14000 rpm for 30 minutes at 4°C. After discarding the 
supernatant, the DNA was washed with 500 µl of 70% Ethanol and centrifuged at 14000 rpm 
for 5 minutes at 4°C. The purified DNA was then dried in a speed vacuum and resuspended in 
20 µl of distilled water. 
 
 
SEQUENCING APPROACHES 
Different techniques were employed in order to identify the causative mutations of each patient. 
Specifically, patients were analyzed through Sanger sequencing or next generation sequencing 
approaches targeted to the exome or to a cluster of selected gene.  
 
SANGER SEQUENCING 
The genes of interest were amplified with primers flanking the intron-exon boundaries with the 
GoTaq® Flexi DNA Polymerase (Promega, Madison, WI, USA) with the following protocol: 
 
H2O    13,875 µl    
Buffer 5x   5 µl    95°C x 5’ 
dNTPs 2 mM   2,5 µl    95°C x 30’’ 
MgCl2 25 mM  1,5 µl    Ta°C x 30’’     x 35 cycles 
Primer Forward (25 µM) 0,5 µl    72°C x 30’’ 
Primer Reverse (25 µM) 0,5 µl    72°C x 5’ 
Taq (5 U/µl)   0,125 µl   4°C ∞ 
DNA (50 ng/µl)  1 µl 
 
PCR products were sequenced with the Big Dye terminator v3.1 Sequencing Kit following the 
manufacturer’s protocol and run on the ABI PRISM 3130xl Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA). Electropherograms were analyzed with the ChromasPro 
Software version 1.7.6 (Technelysium Pty Ltd, Tewantin QLD, Australia). 
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TARGETED GENE PANEL 
Targeted next generation sequencing was based on the design of a custom-made gene panel for 
the Personal Genome Machine (Ion Torrent PGM) with the AmpliSeq Designer Tool (Life 
Technologies, Darmstadt, Germany). The designed panel amplifies 75 kb of selected genomic 
sequences including the five known CdLS-associated genes, with an estimate coverage of 
>95%. After quantification with the Qubit® 2.0 Fluorometer (Life Technologies), libraries 
were prepared using 20 ng of gDNA as starting template with the Ion AmpliSeq Library Kit 
(Life Technologies) according to the manufacturer’s instructions. 
IonSphere particles were loaded with the clonally amplified templates through the Ion PGM 
Template OT2 200 Kit; the loaded template positive particles were then sequenced on the Ion 
316v2 TM Chip with the Ion PGM Sequencing 200 Kit v2 (Life Technologies). Given the high 
frequency of mosaic mutations in CdLS, the filtering process was adjusted to a low stringency 
protocol that excluded only those variants that were represented in less than 5% of the total 
reads. 
 
SNaPshot ASSAY 
SNaPshot assays (SNaPshot® Multiplex Kit, Life Technologies) were used to confirm low 
percentage variants emerged from the targeted gene panel. In fact, this primer-extension based 
assay allows the detection of DNA sequence alterations with a very high sensitivity by the use 
of fluorescent-labeled ddNTPs.  
The region of interest was amplified with the GoTaq® Flexi DNA Polymerase (Promega) as 
previously described. The PCR product was purified with ExoSAP-IT® (Affymetrix, Santa 
Clara, CA, USA) following the manufacturer’s instructions.The SNaPshot reaction was carried 
out as follows: 
     
H2O    1 µl     
SNaPshot Multiplex Ready      96°C x 10’’ 
Reaction Mix   5 µl    50°C x 5’’       x 25 cycles 
Sequencing primer (2 μM) 1 µl    60°C x 30’’ 
Purified PCR   3 µl    4°C ∞ 
    
 
SNaPshot samples were run on the ABI PRISM 3130xl Genetic Analyzer (Applied 
Biosystems) and evaluated with the GeneScan® 4.0 Analysis Software (Life Technologies). 
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EXOME SEQUENCING 
DNAs were assayed for quality and quantity with the Qubit® 2.0 Fluorometer (Life 
Technologies).  
The TruSeq Exome Enrichment Preparation Kit (Illumina, San Diego, CA, USA) was used for 
exome library preparation following the manufacturer’sprotocol. Briefly, 2 µg of gDNA were 
fragmented by Covaris E220; subsequently, end repair, A-tailing, adapter/barcode ligation and 
clonal amplification were performed.  
The pooled libraries, at a final concentration of 8 pMol, were then sequenced on the Illumina’s 
HiSeq 2500 system (Illumina). 
For bioinformatic analysis, read tags were aligned with the human reference genome (hg19) 
using bwa 0.6.1 (Li and Durbin, 2010). After removing duplicate and off-target reads, GATK 
(DePristo et al., 2011) was used to perform a joint call of SNPs and Indels. Variants were 
filtered after Variant Quality Score Recalibration and annotated to dbSNP using SnpSift. 
Functional impact of each variant was predicted using snpEff (Cingolani et al., 2012). Variants 
that were predicted to impact the coding sequences and with a frequency in the population 
lower than 2% were retained. Resulting variants were filtered according to a dominant/de novo 
inheritance model. 
 
CGH-ARRAY 
Peripheral blood DNA samples were tested with the qChip Post oligonucleotide microarray 
(Quantitative Genomic Medicine Laboratories, Barcelona, Spain). This CGH-array comprises 
60,000 probes mainly located in pericentromeric and subtelomeric regions, as well as regions 
associated to syndromes caused by recurrent genomic alterations. The overall median probes 
spacing is 35 Kb and the resolution is of  100-125Kb.  
After hybridization of the DNA of the patients and of the reference DNA, slides were scanned 
and analyzed for relative gain or loss of fluorescent signals. Genomic region analyses were 
performed according to the human reference sequence build 36.1 (hg18) with the Genomic 
Workbench software. 
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EXPRESSION STUDIES 
The level of expression of SMC1A was assessed in seven female patients carrying missense 
mutations. The X-inactivation status of each patient was first evaluated in order to discriminate 
between a random or skewed X-inactivation. Subsequently, Real Time PCR and 
semiquantitative Western Blot were performed in order to assess the level of expression of the 
SMC1A transcript and of the SMC1A protein, respectively. Lastly, a pyrosequencing assay was 
carried out in order compare the expression of the wild type and mutant alleles. 
 
X-INACTIVATION ANALYSIS 
Detection of the X-inactivation status was performed at the HUMARA (Human Androgen 
Receptor gene) and DXS6673E loci. For each sample, 250 ng of gDNA extracted from blood 
or LCLs were digested with the appropriate enzymes. 
Digestion of the HUMARA locus was performed with 2.5 U of the methylation sensitive 
restriction enzymes HhaI and HpaII (New England Biolabs, Ipswich, Massachusetts, USA), 
while the digestion of the DXS6673E locus was performed with 5 U of HhaI and RsaI (New 
England Biolabs). In both cases, gDNA was digested overnight at 37°C, and enzymes were 
inactivated for 20 minutes at 80°C. Additionally, a no enzymes control was set up, and a male 
control was additionally digested in order to verify the completeness of enzymatic cleavage. 
Digested and undigested samples were subsequently PCR-amplified; the HUMARA locus was 
amplified with the Fw 5’-FAM-TCCAGAATCTGTTCCAGAGCGTGC-3’ and Rev 5’-
GCTGTGAAGGTTGCTGTTCCTCAT-3’ primers, while the DXS6673E locus was amplified 
with the following primers: Fw 5’-FAM-ATGCTAAGGACCATCCAGGA-3’ and Rev 5’-
GGAGTTTTCCTCCCTCACCA-3’.  
PCR products were separated on the ABI PRISM 3130xl Genetic Analyzer (Applied 
Biosystems) and the GeneScan® 4.0 Analysis Software (Life Technologies) was used to 
determine peak position and area intensity of each allele. The level X-inactivation was 
calculated by dividing the ratio of the allele peak areas in the digested sample by the ratio of the 
allele peak areas in the undigested sample. 
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RNA EXTRACTION AND cDNA SYNTHESIS 
RNA extraction was performed from blood or LCLs. RNA isolation from blood was performed 
using the Tempus Spin RNA Isolation Reagent Kit (Applied Biosystems) according to 
manufacturer’s instructions. Extraction from LCLs was instead performed with the TRI reagent 
RNA Isolation Reagent (Sigma-Aldrich, St. Louis, MO, USA). Subsequent treatment with 
DNase I (RNase-free, New England Biolabs) was carried out on all RNA samples in order to 
avoid genomic DNA contaminations. 
The High Capacity cDNA Reverse Transcription Kit (Applied Biosystem) was used to retro-
transcribe 250 ng of RNA with random examers. cDNA synthesis was performed in two 
independent experiments for each sample.  
 
REAL TIME PCR 
The expression level of the SMC1A transcript was assessed by the use of the Real Time PCR 
assay. The investigation was run on the OneStep Real Time PCR System Instrument (Applied 
Biosystems). The TaqMan gene expression assay (assay ID: Hs01091953-m1; Applied 
Biosystems), spanning the junction between exons 19 and 20 of SMC1A, was used to carry out 
the Real Time PCR reaction. Based on efficiency and stability experiments, the RPLP0 gene 
was selected as endogenous normalizer and amplified with the TaqMan gene expression assay 
ID:4333761F (Applied Biosystems).  
Relative gene expression was determined using the ΔΔCt method, as previously described 
(Livak and Schmittgen, 2001). 
 
PROTEIN EXTRACTION AND WESTERN BLOT 
LCLs were lysed using lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 1% NP-40, 0.25% 
deoxycholic acid) and a protease inhibitor cocktail (Roche, Mannheim, Germany). The 
suspension was incubated on ice for 30 minutes with occasional inversion to obtain complete 
lysis. The lysate was centrifuged at 14000 rpm for 25 minutes at 4°C. The supernatant (whole 
cell lysate) was stored at -20°C. Protein concentration was determined through the BCA 
Protein Assay Kit (Pierce, Rockford, IL, USA) according to the manufacturer’s protocol with 
the ND-1000 Spectrophotometer (Thermo Fisher Scientific Inc., NanoDrop Products). 
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For each sample, 20 µg of proteins were supplemented with Laemmli buffer (60 mM Tris-Cl 
pH 6.8, 2% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.01% bromophenol blue) and 
denatured at 95°C for 5 minutes. Proteins were separated by 8% SDS polyacrylamide gels and 
then transferred by electroblotting to a polyvinylidene fluoride (PVDF) membrane (Roche). 
Subsequently, membranes were washed twice in PBS-T (100 mM NaCl, 80 mM Na2HPO4, 20 
mM NaH2PO4, 0.3% Tween20) and non-specific binding was blocked by incubating the 
membranes in 5% skimmed milk in PBS-T for 1 hour at room temperature. Membranes were 
incubated overnight at 4°C in agitation with the respective antibodies, namely the rabbit anti-
SMC1A antibody (1:2000) (ab21583; Abcam, Cambridge, UK) and the mouse anti-GAPDH 
antibody (1:12500) (ab8245; Abcam), both diluted in PBS-T. After four washing steps in PBS-
T, the membranes were incubated at room temperature for one hour in agitation with the HRP-
conjugated secondary antibodies diluted in PBS-T: the goat anti-rabbit IgG (1:10.000) (sc-
2004; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the goat anti-mouse IgG 
(1:25000) (sc-2005; Santa Cruz Biotechnology) were used for SMC1A and GAPDH detection, 
respectively. After four washes in PBS-T and two washes in PBS, bound antibodies were 
detected using enhanced chemiluminescence (Westar ηC; Cyangene, Bologna, Italy). 
Blot images were acquired with GboxChemi XT4 system (Syngene, Cambridge, UK) and 
semiquantitative analysis of the SMC1A protein expression was performed using the Gene 
Tools Gel Analysis software (Syngene) after normalization with the expression of the GAPDH 
protein. 
 
PYROSEQUENCING ASSAY 
Pyrosequencing is a quantitative technique based on the activity of the luciferase enzyme. 
Briefly, pyrosequencing consists of five main steps (Fig.13): 
1. The sequence of interest, after being amplified, is incubated with the four different 
enzymes DNA polymerase, ATP sulfurylase, luciferase and apyrase and the two 
substrates Adenosine 5'-phosphosulfate (APS) and luciferin.  
2. The four dNTPs are added one by one. Every time a dNTP is added, two different 
scenarios might occur: in the first case, the dNTP is degraded by the apyrase because 
there is no complementarity with the PCR-template. In the second scenario, the dNTP is 
complementary to the template, and the DNA polymerase incorporates it to the newly 
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forming strand, thus determining the release of one molecule of inorganic 
pyrophosphate (PPi) for each dNTP that has been added.  
3. After the release of the PPi and in the presence of the substrate APS, the ATP 
sulfurylase is able to catalyze the generation of one molecule of adenosine triphosphate 
(ATP) for each molecule of PPi that has been released. The so formed ATP is then used 
by the luciferase to convert its substrate luciferin into oxyluciferin with emission of 
light. The amount of produced light is directly proportional to the amount of produced 
ATP, and so to the amount of PPi that was released, and consequently to the number of 
dNTPs that were incorporated to the newly forming strand. The emitted light is then 
captured by a Charged Coupled Device (CCD) and converted into a single peak in the 
program generated by the analysis software. The height of the peak is directly 
proportional to the number of incorporated dNTPs.  
4. The apyrase catalyzes the degradation of the dNTPs which were not incorporated into 
the new DNA strand. 
5. Another dNTP is added, and the cycle starts over.  
 
 
Figure 13. Diagram of operation of pyrosequencing 
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For the run, the target region was amplified in a 50 µl reaction using the GoTaq Flexi DNA 
polymerase (Promega) and a specific couple of primers, one of which biotinylated. The 
analysis was performed with the Pyro Gold Reagent Kit (Qiagen). Briefly, 40 µl of biotinylated 
PCR product were mixed for 15 minutes at 1400 rpm with 40 µl of  a Binding Mix made up of 
37 µl of Binding Buffer (10 mM Tris-HCL; 2 M NaCl; 1 mM EDTA; 0.1 % TweenTM 20; pH 
7,6) and 3 µl of Streptavidin-Sepharose Beads. The PCR product bound to the beads was then 
denatured and washed with a vacuum pump. The resulting single strand biotinylated PCR 
product bound to the beads was hybridized with the sequencing primer at a final concentration 
of 2 µM in a 96 wells PSQ Plate (Qiagen) and incubated at 80°C for 2 minutes. The plate was 
then transferred to the Pyro MarkID instrument (Qiagen). The PyroMark Q96 ID Software 2.5 
(Qiagen) was used for the analysis. 
 
 
PROTEIN-PROTEIN INTERACTION STUDIES 
Protein-protein interaction studies were carried out in order to verify putative interactions of the 
subunits of the cohesin complex with other transcription factors. 
 
CLONING 
PCR based cloning was used to place DNA fragments encoding for the gene of interest into the 
backbone of the vectors needed for the yeast two hybrid assay.  
PCRs were carried out using primers containing the desired restriction sites at the 5’ position 
and with the high fidelity polymerase TaKaRa primeSTAR GXL DNA Polymerase (Clontech, 
Saint-Germain-en-Laye, France) with the following protocol: 
 
H2O    30 µl    
Buffer 5x   10 µl    98°C x 1’ 
dNTPs 10 mM  4 µl    98°C x 10’’   
 Primer Forward (10 mM) 1,5 µl    Ta°C x 15’’     x 35 cycles 
Primer Reverse (10 mM) 1,5 µl    68°C x 1’x kb 
Taq (5 U/µl)   1 µl    68°C x 5’ 
cDNA    2 µl    4°C ∞ 
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In order to produce PCR fragments suitable for a TA-cloning, 0,25 µl of Taq Poymerase (MP 
Biomedicals, Santa Ana, CA, USA) were added to the PCR reaction after the run, and the tubes 
were then incubated at 72°C for 20 minutes. 
PCR fragment were run on 1% agarose gel and the specific band corresponding to the fragment 
of interest was cut out. Gel extraction was subsequently performed with the QIAquick Gel 
Extraction Kit (Qiagen) according to the manufacturer’s instruction.  
The purified fragment was ligated with the shuttle vector pGEM®-T Easy (Promega) by the 
use of the T4 DNA Ligase (Promega). E. coli DH5α cells were then chemically transformed 
with the recombinant DNA construct and plated onto LB agar plates containing 100 μg/ml of 
ampicillin, in order to specifically select the transformed bacterial cells. Transformed bacteria 
containing the plasmid of interest were grown overnight at 37°C at 225 rpm in 3 ml of LB 
medium supplemented with 3 µl of ampicillin. Plasmids were then extracted using the 
QIAGEN Plasmid Mini Kit (Qiagen) following the manufacturer’s instructions, digested with 
the appropriate restriction enzymes and run on 1% agarose gel in order to check the restriction 
profile. Clones presenting the right profile were sequenced in order to verify the absence of 
mutations. Wild type plasmids were then subcloned into the expression vectors of the yeast two 
hybrid assay, namely pGADT7 and pGBKT7 (Clontech). Transformed bacteria containing the 
plasmid of interest were grown overnight at 37°C at 225 rpm in 50 ml of LB medium 
supplemented with 50µl of antibiotic. Plasmids were then extracted using the QIAGEN 
Plasmid Midi Kit (Qiagen) following the manufacturer’s instructions. 
 
YEAST TWO HYBRID ASSAY 
The yeast two hybrid assay is used to detect protein-protein interactions (Fig.14). The 
technique is highly sensitive and is able to identify also weak and transient interactions. This 
assay is based on the properties of the yeast transcriptional activator GAL4, which can be 
divided in two domains: one DNA binding domain (BD) responsible for the interaction of the 
protein with the DNA, and one activation domain (AD) responsible for the transcriptional 
activation of the target gene. In the yeast two hybrid assay, a gene of interest (bait gene) is 
fused to the GAL4 BD, while a putative interactor (prey gene) is expressed as a fusion to the 
GAL4 AD. If the proteins encoded by the bait and prey genes interact, the BD and AD domains 
of the GAL4 are brought into proximity, thus activating the transcription of four reporter genes 
in the AH109 yeast strain, namely ADE2, HIS3, MEL1 and LacZ, which confer nutritional 
advantage to the transformed yeasts. 
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Figure 14. Schematic representation of the yeast two hybrid assay 
 
Transformation of the yeast AH109 strain was carried out with the lithium acetate method 
(Gietz and Woods, 2002).  
Yeasts growing on an agar plate were inoculated in 5 ml of YPD medium (Yeast Extract-
Peptone-Dextrose) and grown for 2-3 days at 30°C and 250 rpm (pre-culture). The day of the 
transformation, the entire pre-culture was poured into 50 ml of YPD medium and grown at 
30°C at 250 rpm for 5-6 hours. Once the desired density was reached, yeasts were centrifuged 
at 3000 rpm for 5 minutes and then washed with 20 ml of sterile water. Two other washing 
steps were subsequently performed: one in 1 ml 1x TE Buffer (Tris/EDTA) and one in 1 ml of 
1x TE/LiAc (TE/Lithium Acetate). The resulting pellet was resuspended in 250-300 µl 
TE/LiAc. The transformation mix was prepared as follows: 50 µl of yeasts suspension, 5 µl of 
salmon sperm, 300 µl of PEG 40 (Polyethylenglycol) and 1 µg of each midi preparation (bait 
and prey plasmids). After vortexing, the transformation mix was incubated at 30°C for 30 
minutes. Subsequent heat-shock was carried out at 42°C for 15 minutes, followed by two 
minutes on ice. The entire transformation mix was then plated on -2 SD Plates. Three or four 
days after the transformation, -2 and -4 star plates were prepared and incubated at 30°C. 
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EXPRESSION CONTROLS 
Immunoblotting was performed in order to verify the expression of the protein of interests. 
Liquid cultures were established by inoculating yeasts in 3 ml of -2 SD medium and grown for 
2-3 days at 30°C at 250 rpm. The liquid culture was then centrifuged for 5 minutes at 3000 
rpm. After discarding the supernatant, the yeast pellet was freezed with liquid nitrogen and 
subsequently heat-shocked at 42°C. The freezing-thawing step was repeated five times in order 
to determine the lysis of the cell wall. The resulting lysed yeasts were resuspended in 50 µl of 
Laemmli Buffer and denatured at 95°C for 5 minutes. 
Proteins were separated on 10% SDS polyacrylamide gels and then transferred by 
electroblotting to a polyvinylidene fluoride (PVDF) membrane (Roche). Subsequently, 
membranes were incubated with the blocking solution (4% milk in PBS) for 1 hour at room 
temperature, in agitation. Membranes were incubated overnight at 4°C in agitation with the 
respective antibodies, namely the rabbit anti-GAL4 (DNA binding domain) antibody (06-262; 
Merck Millipore, Billerica, MA, USA) and the rabbit anti-Gal4 (Activation Domain) antibody 
(G9293; Sigma-Aldrich), both diluted in 1:1000 in 4% milk. After four washing steps in PBS, 
membranes were incubated at room temperature for 90 minutes in agitation with the HRP-
conjugated secondary antibody goat anti-rabbit IgG (sc-2004; Santa Cruz Biotechnology) 
diluted in 4% milk. After four more washes in PBS, bound antibodies were detected using 
enhanced chemiluminescence (Westar ηC; Cyangene). Blot images were acquired with 
GboxChemi XT4 system (Syngene). 
 
Co-IMMUNOPRECIPITATION 
Co-immunoprecipitation was performed to confirm the protein-protein interactions observed 
with the yeast two hybrid assay. 70 millions of HeLa cells were used for the analysis. Cells 
were harvested and washed with 1 ml of PBS. The lysis was performed with 500 µl of RIPA 
buffer (50 mM HEPES, 1 mM EDTA, 1% NP40, 0,5 M LiCl) and 2 µl of protein inhibitor 
cocktail (Roche).  
Briefly, 100 µl of beads (Affi-Prep® Protein A Matrix, Bio-Rad, Hercules, CA, USA) were 
transferred to a 1,5 ml Eppendorf tube and pelleted at 2500 rpm for 2 minutes at 4°C. The 
pellet was then washed twice with 1 ml of PBS/BSA (5 mg/ml) and resuspended again in 1 ml 
of PBS/BSA by gently inverting. 10 µl of the anti-NIPBL antibody (A301-779A, Bethyl 
Laboratories Inc, Montgomery, TX, USA) or anti-SMC3 antibody (A300-060A, Bethyl 
57 
 
Laboratories Inc) were added to the resuspension, which was then incubated for 5-6 hours in 
agitation at 4°C in order to immobilize the antibody on the beads. After the incubation, the 
complexes beads-antibody were centrifuged at 2500 rpm for 2 minutes at 4°C and resuspended 
in the HeLa cell lysate. A overnight incubation in agitation at 4°C was performed to let the 
protein of interest and its interactors bind the antibody immobilized on the beads. After 
centrifugation, the supernatant (unbound fraction) was transferred to a new tube, while the 
beads pellet was washed twice with 1 ml of RIPA buffer. The pellet was then resuspended in 50 
µl of Laemmli buffer and denatured at 95°C for 5 minutes (Immuno-precipitated fraction). 100 
µl of unbound fraction were mixed with 100 µl of Laemmli buffer and denatured at 95°C for 5 
minutes. Immunoblotting was performed on both fractions using the following antibodies for 
the detection of the proteins: rabbit anti-NIPBL antibody (A302-778A, Bethyl Laboratories 
Inc), mouse anti-SMC3 antibody (A300-060A, Bethyl Laboratories Inc) and mouse anti-SNF5 
antibody (ab58209, Abcam). 
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RESULTS 
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SEQUENCING ANALYSIS OF THE KNOWN CdLS-
GENES 
Sequencing analysis was carried out on an internationally assembled cohort consisting of more 
than 200 patients with a diagnosis of CdLS or with overlapping phenotypes resembling features 
characteristic for CdLS. 
Sequencing analyses were performed by Sanger sequencing and targeted gene panel in order to 
identify the causative mutation underlying the syndrome. When possible, the analysis was 
performed on different tissues to allow the detection of mosaic mutations.  
 
NIPBL 
By our investigations we could identify 109 distinct mutations in the NIPBL gene in 131 
individuals. The identified mutations comprise 37 missense substitutions (34%), 28 out-of-
frame deletions (25%), 12 nonsense mutations (11%), 25 splicing variants (23%), 3 in frame 
deletions/insertions (3%) and 4 deletions of one or multiple exons (4%). The alignment of the 
NIPBL protein sequence of six different organisms showed a high level of conservation of the 
mutant residues during evolution. Recurrence was not observed for any of the identified 
variants. 
Mutations localize throughout the entire gene without mutational hotspots. Among the 109 
mutations, 26 reside in exons coding functional domains. The most affected domains are the 
large caldesmon domain (11 mutations) and the HEAT repeats (9 mutations). In addition, 
sequence variants were also observed in the QR-rich region (1 mutation), in the nuclear export 
signal (1 mutation), in the DNA-binding domain (1 mutation) and in a region enriched in 
prolin, glutamic acid, serine and threonine (PEST, 3 mutations). 
Somatic mosaicism was identified in nine out of 131 patients (7%). The mosaic variants 
include three missense substitutions, two out-of-frame deletions, two splicing and two nonsense 
mutations. Patients carrying these variants present with variable phenotypes. 
Out of the nine mosaic mutations, three appear of particular interest because they were not 
detectable by Sanger sequencing neither using DNA extracted from blood nor using DNA 
extracted from buccal mucosa. Solely through high-coverage targeted next generation 
sequencing we were able to detect a very low amount of mutant reads on buccal mucosa DNA 
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(published as Braunholz et al., 2015). All mutations were confirmed by SNaPshot analysis and 
Sanger sequencing of DNA extracted from fibroblasts. 
The three patients carrying the low grade mosaic variants are all characterized by intellectual 
disability, a low weight and microcephaly (Fig.15). Patient A carries the nonsense mutation 
c.4094T>A, p.L1365* affecting exon 18 and represented in 17% of 64 reads. This patient, a 2-
year-old girl, displayed typical CdLS facial features including synophrys, long eyelashes, long 
philtrum and thin upper lip. In addition, she presented with strabismus, feeding problems, 
GERD, restriction of elbow movements and transverse palmar crease. Patient B is a 19-year-
old girl harboring a missense substitution in exon 23 (c.4751T>G, p.L1584R; 13% of 93 reads). 
She suffered from GERD and displayed a very characteristic CdLS facies with the following 
features: short neck, brachycephaly, low anterior hairline, depressed nasal bridge, long and 
smooth philtrum and thin lips. Lastly, patient C, a 6-year-old girl, carries a variant in the splice 
site of intron 27 that determines the skipping of the entire exon 27, thus resulting in a frame-
shift deletion of 103 bp (c.5328+1G>C, p.M1743Sfs*35; 21% of 267 reads). This patient 
presented with mild facial features and other major complications including a severe motor and 
verbal developmental delay and a brain tumor detected at the age of nine months. The presence 
of hemihypoplasia was the only feature suggestive for a mosaic mutation.  
 
Figure 15. Photographs and electropherograms of the three CdLS patients carrying mosaic mutations in NIPBL that were 
detectable by Sanger sequencing only on DNA extracted from fibroblasts (from Braunholz et al., 2015) 
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SMC1A 
(Published as Gervasini et al., 2013) 
Mutations in SMC1A were identified in eight patients with different ethnic origins including 
Europe, North Africa and South America. The eight patients comprise one male and seven 
females with ages ranging from 3 to 15 years (Fig.16).  
 
 
Figure 16. Facial appearance of seven out of the eight CdLS patients harboring mutations in the SMC1A gene. For four 
patients, pictures were taken at two different ages. For each patient, the respective mutation and the identification number are 
indicated below the photographs (from Gervasini et al., 2013) 
 
All patients displayed the characteristic facial features of CdLS, including thick and arched 
eyebrows, long eyelashes, anteverted nares, a long philtrum and thin lips with downturned 
commissures. Their clinical presentation ranges from mild to severe, with patients 1 and 8 
being the most severely affected. Intra-uterine growth retardation was reported for all patients, 
while postnatal growth appears to be less affected. No major limb malformations were 
observed. The reported clinical findings included GERD, feeding disorder, pulmonary stenosis, 
mild brain anomalies, supernumerary ribs, aortic coarctation, epilepsy and sensorineural 
hypoacusis. A severe developmental delay is the most striking feature of this cohort: sitting 
independently and walking independently were achieved at a median age of 1 year 4 months 
and 2 years 8 months, respectively; patient 1 was still not able to walk autonomously at the age 
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of 6 years. A moderate to severe cognitive impairment was observed in the entire cohort. 
Speech acquisition appears to be even more delayed, with patients 1, 5 and 6 being still unable 
to speak at the age of 6, 11 and 4 years, respectively. The remaining five patients were able to 
pronounce the first words at a median age of 3 years 6 months. The association of more than 
two words occurred at a median age of 4 years 6 months.  
The identified mutations comprise six missense substitution and one in frame-deletion, namely 
p.V58_R62del, p.R398G, p.V651M, p.R693Q, p.I784T, p.T790Q, p.N1166T and p.L1189F. 
The substitutions p.R398G and p.R693Q affect residues that were previously described in the 
literature, though with a different amino acid exchange (Liu et al., 2009). All variants were 
proven to arise de novo in the patients and none of them was observed in more than 400 X 
chromosomes of healthy individuals.  
The relative positions of each mutation according the localization of the structural domains and 
on the SMC1A/SMC3 heterodimer are depicted in Fig.17a and Fig.17b, respectively. The 
mutations localize throughout the entire protein with the exception of the hinge domain. It is 
worth to be noted that the substitutions p.N1166T and p.L1189F affect the C-terminal ATPase 
cassette, and p.L1189F is the first mutation residing in the functional motif H-loop. All variants 
were predicted to be disease causing by different in silico bioinformatic tools (Polyphen-2, 
SIFT and Mutation Taster). In addition, the alignment of multiple regions of the SMC1A 
protein across nine species highlighted a high level of conservation of the affected residues and 
of the surrounding amino acids.  
 
Figure 17. (a) Schematic representation of the SMC1A protein and of its domains. The position of novel and reported 
mutations are indicated. (b) Schematic representation of the core heterodimer of the cohesin complex with relative position of 
the described mutations (from Gervasini et al., 2013) 
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SMC3 
(Published as Gil-Rodrìguez et al., 2015) 
 
 
Figure 18. Phenotype of the patients harboring mutations in the SMC3 gene so far described in the literature, including the one 
reported in Deardorff et al., 2007 (P6). For each individual, photographs show a frontal view, a lateral view, hands and feet. 
The identification number and the relative mutation are also indicated above each picture (from Gil-Rodrìguez et al., 2015) 
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Sequencing analysis of patients with CdLS or CdLS-overlapping features led to the 
identification of 15 additional mutations in SMC3 in 15 unrelated individuals. 
The phenotypical appearance of these patients is shown in Fig.18. The most characteristic 
clinical feature in this group is a variable level of cognitive impairment. Considerable 
behavioral problems were not observed, and many patients of this cohort were described as 
having friendly personalities. Major limb malformations were also not reported. Typical CdLS 
facial features were observed with the following frequency: low anterior hairline (50%), 
brachycephaly (73%), synophrys (73%), arched eyebrows (93%), ptosis (27%), long eyelashes 
(94%), depressed nasal bridge (47%), anteverted nares (57%), long philtrum (67%), thin upper 
lip (81%), downturned commissures (60%), dental anomalies (38%), high palate (45%) and 
micrognathia (40%). Interestingly, despite often long, the philtrum of these individuals was 
typically not smooth, and only one patient presented with cleft palate.  
The SMC3 mutations so far identified are listed in Table 3 and comprise nine missense 
substitutions, one nonsense mutation and five in-frame deletions, one of which (p.E488del) 
observed in two unrelated patients. The SMC3 protein sequence of nine different organisms 
was aligned in order to verify the degree of conservation of the mutant residues. This analysis 
showed that the conservation can be traced back to yeast for all the amino acids of interest. In 
addition, all the variants were defined as disease causing by three different in silico 
bioinformatic tools (Polyhen-2, SIFT and Mutation Taster). 
ID DNA variant Protein change De novo Exon Protein domain 
P1 c.193T>C p.F47L na 4 Head 
P2 c.703_705del (mosaic) p.T235del + 9 Coiled-coil 
P3 c.707G>C p.R236P + 9 Coiled-coil 
P4 c.859_861dup p.E287dup na 11 Coiled-coil 
P5 c.1200_1202delGTC p.K400_S401delinsN na 13 Coiled-coil 
P6 c.1464_1466delAGA p.E488del + 15 Coiled-coil 
P7 c.1464_1466delAGA p.E488del + 15 Coiled-coil 
P8 c.1462G>A p.E488K + 15 Coiled-coil 
P9 c.1561C>T p.R521* na 16 Hinge 
P10 c.1964G>A p.G655D + 19 Hinge 
P11 c.1997G>C p.G666A + 19 Hinge 
P12 c.2494_2499del p.L832_N833del + 22 Coiled-coil 
P13 c.2515C>T p.R839C na 22 Coiled-coil 
P14 c.2750A>C p.H917P + 24 Coiled-coil 
P15 c.3439C>G p.Q1147E + 27 Head 
P16 c.3644C>T p.T1215I na 29 Head 
Table 3. List of all mutations so far identified in SMC3, including the one reported in Deardorff et al., 2007 (P6). For each 
mutation, the DNA and protein change are indicated. The localization of the mutations with regards to the exons and to the 
functional/structural domains of the protein are also designated. (na=not assessed) 
65 
 
Mutations are scattered across the entire protein without apparent hotspots (Fig.19). 
Interestingly, three mutations affect the highly conserved hinge domain, responsible for the 
interaction with the specular domain of the SMC1A protein. Some of the affected residues 
appear to play an important role in the tertiary structure of the protein. In point of fact, the 
substitution of G655D structurally destabilize the core of the hinge domain. In addition, the 
deletions of T235, R236, R839 and H917, all residing in the coiled-coil domain, are responsible 
for the displacement of the two antiparallel helices.  
 
Figure 19. Schematic representation of the core heterodimer of the cohesin complex with relative position of the described 
SMC3 mutations according to the localization of the functional domains of the protein (from Gil-Rodrìguez et al., 2015) 
 
Besides, Q1147 localizes in the functional D-loop motif, close to interaction surface between 
SMC1A and SMC3 and to the gamma-phosphate of ATP. Therefore, the substitution of this 
polar residue with the negatively charged glutamate amino acid might impair the interaction 
between SMC1A and SMC3 as well as the ATPase activity (Fig.20). 
 
Figure 20. Representation of the predicted tridimensional structure of the SMC3 protein in proximity of the ATPase active 
centre in the presence of a wild type (left) or mutant (right) residue at position 1147. The interaction surface between SMC3 
and SMC1A has been colored with regard to the electrostatic characteristics (blue=positive; red=negative; white=neutral). 
The negatively charged patch that appears in the presence of the mutation close to the gamma phosphate of ATP is highlighted 
(from Gil-Rodrìguez et al., 2015) 
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HDAC8 
Ten distinct mutations in the HDAC8 gene were identified in 11 patients, namely eight females 
and three males (Fig.21). Patients presented with a very broad range of phenotypical features 
that are summarized in Table 4 and include microcephaly (90%), brachycephaly (36%), late 
closure of the anterior fontanelle (36%), low anterior hairline (45%), short neck (90%), 
synophrys (90%), arched eyebrows (90%), long eyelashes (45%), hypertelorism (90%), 
hooding of the eyelids (45%), myopia (54%), astigmatism (45%), strabismus (36%), depressed 
nasal bridge (45%), anteverted nares (54%), broad/bulbous nasal tip (81%), long philtrum 
(36%), smooth philtrum (54%), thin upper lip (72%), downturned commissures (54%), 
micro/retrognathia (90%), widely spaced teeth (45%), highly arched palate (45%), small hands 
(72%), small feet (36%), clinodactyly (45%), proximally set thumbs (63%), short fifth finger 
(54%), hirsutism (63%), pigmentation defects of the skin (36%), gastroesophageal reflux 
(36%), feeding problems in infancy (45%), cryptorchidism (100% of males) and hearing 
problems (63%). Growth retardation, intellectual disability and motor and verbal 
developmental delay were reported in all patients.  
 
Figure 21. Facial features of the patients harboring mutations in the HDAC8 gene. For each patient, the mutation and the 
gender are indicated 
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 Females   Males   General 
frequency Patient number 1 2 3 4 5 6 7 8 Relative 
frequency 
9 10 11 Relative 
frequency X-inactivation 99/1 100/0 17/83 100/0 100/0 100/0 100/0 100/0 - - - 
Head 
Microcephaly + + + + + + + - 87% + + + 100% 90% 
Brachycephaly + + + - - - - - 37% - - + 33% 36% 
Late closure of the 
anterior fontanelle + + na - - - - + 37% - + - 33% 36% 
Eyes 
Arched eyebrows + + + + - + + + 87% + + + 100% 90% 
Synophrys + + + + + - + + 87% + + + 100% 90% 
Hypertelorism + + + + + + + + 100% - + + 67% 90% 
Telecanthus - + - + - - - - 25% - - - 0% 18% 
Myopia/Astigmatism + + + - + - + + 75% + - - 33% 63% 
Strabismus - - - - + - + + 37% + - - 33% 36% 
Hooding of lids - - - - - - + + 25% + + - 67% 36% 
Lacrimal duct obstruction - - - - - na - - 0% - na + 33% 9% 
Nose 
Depressed nasal bridge + + - + - - - - 37% - + + 67% 45% 
Anteverted nares + + - + - + - - 50% - + + 67% 54% 
Long philtrum + - - + - - - - 25% - + + 67% 36% 
Smooth philtrum + + - - - - + + 50% + - + 67% 54% 
Broad nasal tip + + + + + + + + 100% + - - 33% 81% 
Mouth 
Thin lips + + - - - + + + 62% + + + 100% 72% 
Downturned commissures + + - + + - - - 50% - + + 67% 54% 
Micro/Retrognathia + + + + + + - + 87% + + + 100% 90% 
Ears Dysplastic ears + - - + - - - + 37% - - - 0% 27% Hearing problems + - - + + - + + 62% + + - 67% 63% 
Hands 
Small hands - + + + + - + - 62% + + + 100% 72% 
Proximally set thumbs + + + - + - + - 62% + - + 67% 63% 
Clinodactyly 5th finger - + + + - - - - 37% + + - 67% 45% 
Feet Small feet - + + - na - na - 25% na + + 67% 36% Syndactyly of toes - - + - - - - - 12% - - - 0% 9% 
Other 
Cardiac defects + - - + + + - - 50% - + + 67% 54% 
Genitourinary defects - + + - + - - - 37% + + + 100% 54% 
GER - - + - + - + - 37% + - - 33% 36% 
Feeding problems + + + - - - + - 50% - + - 33% 45% 
Seizures - - + - - - - - 12% - + + 67% 27% 
Development 
Growth retardation + + + + + + + + 100% + + + 100% 100% 
Intellectual disability + + + + + + + + 100% + + + 100% 100% 
Psychomotor delay + + + + + + + + 100% + + + 100% 100% 
Behavioral problems na + + - + - - - 37% na na - 0% 27% 
Table 4. Clinical features of the eleven patients with mutations in the HDAC8 gene 
 
The three male patients, who are hemizygous for the mutation, displayed very severe multi-
organ complications including cryptorchidism, vesicoureteral reflux, pulmonary stenosis, 
hypoacusis, inguinal hernia, corpus callosum agenesis and cerebral atrophy. In addition, they 
all showed marked growth retardation and prominent motor and verbal developmental delay. 
Patient 8 even died of pneumonia at the age of two years. Conversely, the eight female patients 
presented with a broad range of clinical features and a variable degree of severity of the 
phenotype. Accordingly, patient 2 presented with the mildest clinical presentation, while 
patient 7 showed the most severe features among females. The observed broad range of 
phenotypes could be partially explained by the X-inactivation status: in point of fact, all 
females except patient 3 were found to carry a completely skewed X-inactivation towards the 
wild type allele on blood DNA.  
The identified variants include one nonsense mutation (p.R166*), one out-of-frame deletion 
(p.F207Nfs*3), one splicing mutation (c.910+1G>A; p.V247Ffs*37) and seven missense 
substitutions (p.S150P, p.C153R, p.N156K, p.T280I, p.P257L, p.C287Y, and p.G320R) 
(Fig.22). Eight mutations are novel, while two affect amino acids (C153 and G320) that were 
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already found to be mutated in the literature (Deardorff et al., 2012b; Kaiser et al., 2014). None 
of these variants was identified in over a hundred of healthy X chromosomes. All mutations 
were proven to affect highly conserved residues and were predicted to be pathogenic by 
different in silico bioinformatic tools (PolyPhen-2, SIFT and Mutation Taster).  
 
Figure 22. Schematic representation of HDAC8 and of its functional domains, with relative position of already described 
(black bars) and novel (green bars) mutations. Stars indicate out-of-frame deletions or nonsense mutations, that lead to an 
early truncation of the protein 
 
Interestingly, the p.T280I missense exchange is shared by two siblings, a boy and a girl 
(patients 6 and 10). Next generation sequencing approaches highlighted the presence of the 
same mutation in a low number of reads on the DNA of the mother (18 of 200 reads). Hence, 
pyrosequencing was performed in order to investigate the suspected mosaicism. The analysis 
was carried out on blood DNA of the affected daughter (patient 6) as a control and on DNA 
extracted from three different tissues of the mother, namely blood, buccal mucosa and urine 
(Fig.23). This analysis pointed out the presence of tissue-dependent level of heterozygosity in 
the mother: while the daughter displayed an equal amount of wild type and mutant alleles, the 
mutation in the mother was totally absent on buccal mucosa, barely detectable on blood (2%) 
and was represented at a rate of 19% on DNA extracted from urine. In addition, X-inactivation 
analysis on blood DNA showed a complete skewing in the daughter (100/0) and a random 
selection of the inactive X-chromosome in the mother (40/60). 
The mother, who presents with short stature and appears cognitively normal, displayed facial 
features reminiscent of CdLS during childhood; anyhow, these features were not discernible 
anymore during adulthood. Both children showed instead CdLS features including intellectual 
disability, growth retardation, patent foramen ovale, microcephaly, hypertelorism, arched 
eyebrows, anteverted nares, micro/retrognathia and thin lips. In addition, the male sibling 
(patient 10) presented with short neck, hooding of the lids, synophrys, ptosis, a depressed nasal 
bridge, long philtrum, downturned commissures, small hands and feet, clinodactyly of the fifth 
finger, cystic renal degeneration, pulmonary stenosis, hypospadias, cryptorchidism, 
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sensorineural hearing loss, feeding problems and seizures. He died at the age of two years 
because of pneumonia.  
 
 
Figure 23. Pyrosequencing analysis of the mother of the siblings harboring the T280I variant on different tissues. The mutation 
is not detectable on buccal swab DNA (0%), barely detectable on blood DNA (2%) and detectable at a rate of 19% on DNA 
extracted from urine 
 
 
 
 
70 
 
OVERALL AND ALLELE-SPECIFIC EXPRESSION OF 
THE SMC1A GENE 
(Published as Parenti et al., 2014) 
 
SMC1A maps at Xp11.22, a region of the X chromosome that partially escapes X-inactivation 
in humans. Genes that localize in this region are characterized by a variable level of expression 
among females and between females and males. In particular, females were reported to express 
SMC1A at a higher level than males, but the ratio between the two genders vary among 
different studies (Craig et al., 2004; Johnston et al., 2008; Liu et al., 2009). Therefore, we 
established a Real Time PCR assay in order to assess the expression level of SMC1A in 17 
healthy controls, namely ten females and seven males. In this way we were able to prove that 
SMC1A expression in females is approximately 50% higher than in males (***P=0,0001; one 
tail Mann-Whitney U test) (Fig.24a). Subsequently, the same investigation was carried out at a 
protein level by mean of semi-quantitative western blot on protein lysates of five LCLs from 
females and four LCLs from males. Our results indicate that SMC1A expression in females is 
approximately 44% higher than in males, as shown in Fig.24b and 24c. (**P=0,0079; one tail 
Mann-Whitney U test). Hence, the examination of both SMC1A transcript and protein 
concordantly showed a higher expression in females as compared to males. 
 
Figure 24. SMC1A expression in the healthy population. (a) Graphical representation of the transcript analysis in seven males 
and ten females, indicating a 50% higher expression of the gene in females as compared to males. (b-c) Graphical 
representation of the protein analysis in four males and five females (b) The histograms indicate the relative expression of 
SMC1A in the female controls in comparison with the average level of expression in the males (set as 1 and represented by the 
horizontal black line) (c) Average expression of the protein in the two groups of controls. Females are shown to express 
SMC1A 44% more than males (from Parenti et al., 2014) 
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We then investigated the SMC1A protein in the CdLS population in order to assess whether the 
presence of mutations could impair the ability of the cell to synthesize the protein or the 
stability of the protein itself. The analysis was performed on five out of the seven CdLS female 
patients identified through the mutational analysis and on two previously described patients 
(Musio et al., 2006; Limongelli et al., 2010). The seven patients, herein indicated as patient 1-7, 
respectively carry the following mutations in SMC1A: p.Q831_D832delinsE, p.L1189F, 
p.N1166T, p.I784T (shared by patient 4 and 5), p.V58_R62del and p.R693Q. Semi-quantitative 
western blot analyses (Fig.25a) could show that all patients express SMC1A at comparable 
levels with few variability among samples (Fig.25b). No differences among the distinct 
mutations were observed. Subsequently, we compared the SMC1A expression of the CdLS 
population with the one of the five female controls. This analysis indicated that there are no 
significant differences in the protein level between the two groups (P=0,5; one tail Mann-
Whitney U test) (Fig.25c). 
 
 
Figure 25. Western blot analysis of the SMC1A protein in a group of CdLS female patients (a) Representative blot showing the 
SMC1A protein (150 kDa) and the normalizer GAPDH (36 kDa) (b) The histograms indicate the relative expression of the 
protein in the CdLS patients in comparison with the average level of expression of the five female controls (set as 1 and 
represented by the horizontal black line) (c) Average expression of SMC1A in controls and patients. No significant difference is 
observed (from Parenti et al., 2014) 
 
Lastly, we investigated the expression of the wild type and mutant alleles in the seven female 
patients with mutations in SMC1A in order to identify a possible differential expression of the 
two alleles. The X-inactivation status was first checked for each patient at the HUMARA or 
DSX6673E loci. A completely skewed X-inactivation was identified in patients 3, 4, 5 and 6. 
The remaining patients presented with a borderline or random X-inactivation. The allele-
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specific expression analysis was carried out by means of pyrosequencing on 15 female controls 
and on six out of seven CdLS patients (patient 6, carrying the p.V58_R62del, was excluded 
from this analysis due to the inability to establish an effective pyrosequencing assay). The SNP 
rs1264011 was used to discriminate the two alleles of the female controls; this SNP is 
characterized by a high level of heterozigosity in different populations and is localized in the 
5’UTR of the gene. Patients were analyzed with assays specific for each mutation. When 
possible, the analysis was carried out on RNA extracted from both blood and LCLs in order to 
verify whether the allele expression ratios might be affected by the type of starting material. In 
this context, no differences in the wild type/mutant ratio were observed between the two pools 
of RNA (Fig.26a). The pyrosequencing assays showed that the expression ratio of the two 
alleles of the SNP in the healthy population was 1:1. Conversely, the average ratio between 
wild type and mutant allele in the CdLS population was 2:1 (Fig.26b). In point of fact, in all 
patients, more than 60% of the total transcript carried the wild type allele, and the greatest 
difference between the wild type and mutant allele was observed in patient 1, carrying the in-
frame deletion p.Q831_D832delinsE, who expressed 73% of wild type allele and 27% of 
mutant allele. 
 
 
 
Figure 26. Results of the pyrosequencing assay (a) Level of expression of the wild type (allele 1) and mutant (allele 2) alleles of 
the SMC1A gene in six CdLS patients. Results from both peripheral blood (PB) and LCLs are shown. (b) Graphical 
representation of the pyrosequencing results. The level of expression of the wild type allele is indicated in blue, while the 
mutant allele is indicated in red. The 1:1 ratio between the two alleles observed in the control group is graphically represented 
as a black line (from Parenti et al., 2014) 
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IDENTIFICATION OF NEW CAUSATIVE GENES 
Mutations in the cohesin-related genes NIPBL, SMC1A, SMC3, RAD21, and HDAC8 are found 
in about 70% of CdLS patients. Hence, additional causative genes might explain the remaining 
30% of cases. In this context, genes functionally related to cohesin or genes responsible for 
clinical entities partially overlapping with CdLS might be able to cover this missing 
heritability. For this reason, we analyzed our cohort of patients with CdLS or CdLS-
overlapping features by different next generation sequencing techniques including exome 
sequencing, targeted gene panel and CGH-array.  
 
IDENTIFICATION OF MUTATIONS IN THE ANKRD11 GENE IN TWO 
PATIENTS WITH A TENTATIVE CLINICAL DIAGNOSIS OF CdLS 
(Published as Parenti et al., 2015) 
Exome sequencing led us to the identification of mutations in the ANKRD11 gene in two 
patients with a tentative diagnosis of CdLS. As previously mentioned, mutations in ANKRD11 
are responsible for KBG syndrome, a rare genetic disorder characterized by growth retardation 
and skeletal anomalies, cognitive impairment, developmental delay and characteristic facial 
features partially overlapping with CdLS, in particular concerning the ocular and peri-nasal 
regions (Ockeloen et al., 2014). 
Patient 1 (Fig.27a-h) is a German female born to healthy and non-consanguineous parents at 37 
weeks of gestation. The Apgar scores at 1 and 5 minutes were 9 and 10, respectively. Birth 
weight was 2350 g (3rd centile), birth length was 46 cm (3rd centile) and the Occipital Frontal 
Circumference (OFC) was 31.5 cm (3rd centile). The patient presented with general muscular 
hypertonia and persistent feeding difficulties. At the age of four months, weight was 5600 g 
(10th centile), height was 59 cm (10th centile) and the OFC was 38.3 cm (<3rd centile). At this 
age some dysmorphic features typical of CdLS were observed, including microcephaly, 
brachycephaly, short neck, open anterior fontanelle, broad eyebrows with synophrys, 
downslanting palpebral fissures, depressed nasal bridge, anteverted nares, long philtrum, thin 
upper and lower lips with downturned commissures and micrognathia. She also displayed 
proximally set thumbs and a mild brachydactyly. At the age of the last clinical evaluation (4 
years) the patient still needed assisted feeding. She was able to sit independently at the age of 
16 months and to walk independently at the age of 20 months, but was still unable to speak, 
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thus indicating a marked speech delay. She also showed intellectual disability and a self-
injurious and aggressive behavior associated with autistic features.  
 
 
Figure 27. Clinical features of the patients harboring mutations in the ANKRD11 gene. (a-h) Patient 1: (a-c) Facial gestalt at 
the age of four months and four years, respectively. (d) Teeth conformation at the age of four years, showing small and widely 
spaced teeth. (e-h) Pictures of the limbs, revealing clinodactyly of the fifth finger, shortened first metacarpal and proximally set 
thumb. (i-k) Patient 2: (i, j) Facial gestalt at the age of 8 and 15 years, respectively. (k) Left hand of the patient, characterized 
by proximally set thumbs and clinodactyly of the fifth finger (from Parenti et al., 2015) 
 
Patient 2 (Fig.26i-k) is an Italian male born to healthy and non-consanguineous parents at 39 
weeks of gestation. Birth weight was 3150 g (25th centile), lenght was 53 cm (90th centile) and 
the OFC was 33 cm (3rd centile). He presented with vesicoureteral reflux, kidney dysplasia, 
GERD and generalized epilepsy. At the age of four years he was able to speak in sentences, 
walk independently and to manage himself in daily life. He showed a moderate intellectual 
disability and an aggressive behavior towards himself and towards others. At the age of 15 
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years, weight was 41.2  kg (3rd centile),  height was 161 cm (10th centile) and the OFC was 54 
cm (3rd centile). The following facial dysmorphisms were observed: low anterior hairline, 
synophrys, broad and arched eyebrows, long eyelashes, high nasal bridge with a broad nasal 
tip, smooth philtrum, thin lips, large mouth, mild micrognathia and macrodontia of the superior 
central incisors. Lastly, he presented with hirsutism, astigmatism and myopia, clinodactyly of 
the fifth finger and proximally set thumbs.  
Both patients received a clinical diagnosis of CdLS during early childhood and were therefore 
analyzed for mutations in the five CdLS genes. The high coverage targeted gene panel could 
not detect any pathogenic variant on DNA extracted from blood, buccal mucosa and 
fibroblasts. Hence, the two patients were selected for a exome sequencing analysis. 
Four de-novo variants were identified in patient 1: a missense mutation in ACAP3 (ArfGAP 
with coiled-coil, Ankyrin repeat and PH domains 3), a possible splicing variant in BMPR2 
(Bone Morphogenetic Protein Receptor 2), a missense mutation in ERC2 (ELKS/RAB6-
interacting/CAST family member 2) and a nonsense mutation in ANKRD11. Different in silico 
bioinformatic tools predicted the variants in the ACAP3, BMPR2 and ERC2 genes to be not 
pathogenic. In addition, no functional overlap between these genes and the cohesin complex 
was identified. Therefore, we focused on the nonsense mutation in ANKRD11, which appeared 
as an ideal candidate because mutations in this gene were recently reported in three patients 
with clinical features reminiscent of CdLS (Ansari et al., 2014). The mutation in ANKRD11, 
namely c.5483G>T; p.S1828*, was found in 836 of 2664 sequencing reads (31%), hence 
raising the suspicion of mosaicism.  
Four variants were also identified in patient 2. Nevertheless, the missense variants in the ZW10 
(centromere/kinetocore protein zw10 homologue), SMC1B (Structural Maintenance of 
Chromosome protein 1B) and ASPM (Abnormal Spindle-like Microcephaly-associated protein) 
genes were all found to be inherited. Therefore, we focused on a four base-pairs deletion in 
ANKRD11, resulting in a premature stop codon. This deletion, c.2297_2300delAGAA;  
p.K766Rfs*10, was found in 13 of 60 sequencing reads (22%), thus suggesting a possible 
mosaic state also for this patient.  
Both ANKRD11 variants were confirmed by Sanger sequencing on DNA extracted from 
different tissues (Fig.28).  
Electropherograms of patient 1 showed an unequal distribution of the wild type and mutant 
alleles on DNA extracted from blood and fibroblasts, further supporting the presence of 
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mosaicism. Conversely, no significant differences between the two alleles were observed in 
three different tissues of patient 2.  
Pyrosequencing was performed in order to determine the role exerted by the putative 
mosaicism in the two patients (Fig.28). This assay could confirm the presence of mosaicism in 
patient 1, while the mutation in patient 2 was excluded to be mosaic. Particularly, the two 
alleles appear to be equally represented on all tissues of patient 2 and on fibroblasts DNA of 
patient 1, while a 70:30 ratio between the wild type and mutant allele was observed on blood 
DNA of this latter patient.  
 
 
Figure 28. Examination of the putative mosaicism by means of Sanger sequencing and pyrosequencing. Multiple tissues were 
analyzed for both patients. On the left, electropherograms of patient 1 suggests an unequal distribution of the wild type and 
mutant alleles, while no differences are observed in the electropherograms of patient 2. On the right, the results of the 
pyrosequencing assays are showed, with the wild type allele indicated in green and the mutant allele indicated in red (adapted 
from Parenti et al., 2015) 
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COHESINOPATHIES ARE BRANCHING OUT: CLINICAL AND 
MOLECULAR CORRELATION BETWEEN CdLS AND CSS 
As previously mentioned, several syndromes represent a differential diagnosis to CdLS. For the 
establishment of our gene panel we focused on the phenotypical overlap between CdLS and 
CSS and on the functional overlap between the protein complexes responsible for these clinical 
entities. Thus, our gene panel comprises the following 16 genes: the five known CdLS genes, 
five genes functionally related to cohesins (STAG1, STAG2, STAG3, HDAC1 and HDAC3) and 
six subunits of the SWI/SNF complex including SMARCA2, SMARCA4, SMARCB1, 
SMARCE1, ARID1A and ARID1B.  
Targeted gene panel and exome sequencing led us to the identification of mutations in different 
subunits of the SWI/SNF complex in four patients with a clinical diagnosis of CdLS. 
Patient 1 (Fig.29a,b) is a German female who carries a missense mutation in SMARCB1, 
namely c.998A>G; p.K333R. Patient 2 (Fig.29c), a boy from the United States, harbors the out-
of-frame deletion in ARID1A c.4682_4779del; p.V1561Afs*9. Patient 3 (Fig.29d) is a German 
boy carrying a splicing variant in ARID1B, namely c.3136-2A>G. Patient 4 (Fig.29e,f), a 
Spanish boy, was found to carry a gross deletion on chromosome six by means of exome 
sequencing. The deletion was subsequently confirmed and defined through CGH-array, which 
showed a loss in copy number at the 6q25.3q26 region spanning ~4.1 Mb[arr 
6q25.3q26(157,377,717-161,484,554)x1 hg18]. The deletion comprises 34 genes, including the 
entire ARID1B.  
Correspondingly, we were also able to find a missense substitution in the NIPBL gene in a 
patient with a clinical diagnosis of CSS (patient 5, Fig.29g,h). The mutation (c.6886A>G; 
p.S2296G) affects the HEAT repeats, indispensable for protein-protein interactions. This 
patient is of particular interest because she was described as CSS unsolved case in a paper of 
2013 (Wieczorek et al., 2013). In fact, she presented with clinical findings consistent with a 
diagnosis of CSS, namely a coarse face, low frontal hairline, synophrys, thick eyebrows, a 
broad nose with upturned nasal tip, a large mouth, hypoplasia of distal phalanges and 
fingernails, short metacarpals and metatarsals, delayed bone age, scoliosis and hirsutism. She 
also displayed severe intellectual disability, psychomotor delay, an autistic behavior, hearing 
loss and seizures.  
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Figure 29. Phenotype of the patients. (a,b) Pictures taken at different ages of patient 1, carrying the missense mutation in 
SMARCB1. (c) Facial features of patient 2, harboring the out-of-frame deletion in ARID1A. (d) Facies of patient 3, carrying 
the splicing mutation in ARID1B. (e,f) Frontal and lateral view of patient 4, presenting with the deletion of chromosome 6 
encopassing the entire ARID1B gene. (g,h) Pictures of the CSS patient (patient 5) carrying a missense mutation in NIPBL. To 
be noted the presence of hypoplasia of the distal phalanges and of the fingernails, clinical findings characteristic of CSS 
 
Importantly, a recent paper could demonstrate a direct interaction between the cohesin loader 
NIPBL and the SWI/SNF complex (Lopez-Serra et al., 2014). Particularly, in yeast, NIPBL 
was found to be recruited by the SWI/SNF complex to broad nucleosome-free regions. It is 
therefore tempting to speculate that NIPBL and the SWI/SNF complex cooperate in order to 
mediate the transcriptional regulation of multiple genes (Lopez-Serra et al., 2014). Based on 
this hypothesis, we checked for a putative direct interaction between cohesin-related proteins 
and subunits of the SWI/SNF complex by a yeast two hybrid approach (Y2H). Hence, we 
generated Y2H plasmids containing cohesin-related proteins as a BD-bait and SWI/SNF 
subunits as a prey in a AD-fusion-construct. In detail, the following expression constructs were 
generated: NIPBL F1 (aa 1-879), NIPBL F2 (aa 728-1555), NIPBL F3 (aa 1501-2470), NIPBL 
F4 (aa 2121-2804), RAD21 full length, SMARCB1 full length, SMARCA5 F1 (aa 1-668), 
SMARCA5 F2 (aa 558-1052), ARID1B F1 (aa 1-668), ARID1B F2 (aa 562-1273), ARID1B 
F3 (aa 1188-1818), ARID1B F4 (aa 1720-2249), ARID1A F1 (aa 1-708), ARID1A F2 (aa 602-
1297), ARID1A F3 (aa 1196-1871), ARID1A F4 (aa 1755-2285), SMARCA2 F1 (aa 1-701) 
and SMARCA2 F2 (aa 601-1590). Because of the peculiarity of their protein structures, 
SMC1A and SMC3 expression constructs were not generated.  
Through this technique we were able to detect an interaction of NIPBL fragment F1 (aa 1-879) 
with SMARCB1 (Fig.30).  
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Figure 30. Yeast two hybrid –4 plates (a) Negative control NIPBL F1-BD + AD-empty (b) Positive control NIPBL F1-BD + 
MAU2-AD (c) Positive growth observed for those yeasts which were transformed with NIPBL F1-BD and SMARCB1-AD, 
indicating the existence of an interaction between the two proteins 
 
We subsequently performed a Co-Immunoprecipitation (Co-IP) assay in HeLa cells in order to 
confirm the interaction between NIPBL and SMARCB1. By means of Co-IP we were able not 
only to confirm this interaction, but also to prove the existence of an interaction between SMC3 
and SMARCB1.  
We then assessed whether the identified interactions take place before or after the binding of 
the proteins to the DNA. Therefore, we separated the chromatin-bound and the soluble proteins 
of the cells and performed Co-IP on both protein fractions (Fig.31). By this we could 
demonstrate that the interaction of SMARCB1 with SMC3 as well as NIPBL takes place on 
both fractions, thus suggesting that cohesin and the SWI/SNF complex interact before binding 
to the DNA.  
                          
 
Figure 31. Results of the Co-IP experiments performed on two cellular fractions of HeLa cells: soluble proteins (left) and 
chromatin-bound proteins (right). A positive SMARCB1 signal is detected on the IP fraction of the α-NIPBL Co-IP as well as 
on the IP fraction of the α-SMC3 Co-IP, thus indicating that the interaction of SMARCB1 with the cohesin-related proteins 
takes place in both protein fractions. Inp (Input) represents the whole cell extract which was loaded as a positive control 
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Subsequently, we created smaller fragments of NIPBL and SMARCB1 in order to narrow 
down the protein domain responsible for the interaction. The new NIPBL fragments (Fig.32) 
include NIPBL F1-1 (aa 1-193), which comprises the domain responsible for the interaction of 
NIPBL with MAU2 (aa 1-38) and NIPBL F1-2, which does not contain any particular 
functional or structural domain. Similarly, SMARCB1 F2 (aa 157-404) contains the functional 
domain SNF5, while no functional or structural domains are localized in SMARCB1 F1 (aa 1-
193). In addition, all the mutations so far reported in the literature in association with CSS 
(p.K363N, p.K364del, p.R377H) as well the mutation identified in patient 1 of our cohort 
(p.K324R) localize within the second fragment of SMARCB1. The Y2H assay performed on 
the smaller fragments showed that the interaction involves the first fragment of NIPBL and the 
second fragment of SMARCB1. 
 
 
Figure 32. Schematic representation of the protein fragments created for the yeast two hybrid assay in order to narrow down 
the domains responsible for the interaction between NIPBL and SMARCB1. The first 879 aa of NIPBL were subdivided into 
two fragment: the first fragment (aa 1-193) comprises the domain of NIPBL responsible for the interaction with MAU2, 
whereas no functional or protein-protein interaction domains localize within the second fragment (aa 144-879). The full-length 
SMARCB1 was also subdivided in two fragments: the first fragment (aa 1-193) does not contain any relevant domain, while the 
second fragment (aa 157-404) contains the functional domain of the protein (SNF5 domain). In addition, all the mutations so 
far identified (red bars) localize in this fragment. Our experiments showed that the interaction between the two proteins is 
mediated by the first fragment of NIPBL and the second fragment of SMARCB1. 
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MUTATIONAL FREQUENCIES AND GENOTYPE-
PHENOTYPE CORRELATION 
CdLS is characterized by a wide clinical expressivity: the reported facial features as well as the 
number and severity of complications affecting other organs or systems are highly variable 
among patients (Kline et al., 2007). The broad range of phenotypes is partially accounted for by 
the genetic heterogeneity that underlies the syndrome. Up to date, mutations in five different 
genes have been reported in association with CdLS. These five genes comprise the structural 
components of the cohesin complex SMC1A, SMC3 and RAD21 and the regulators NIPBL and 
HDAC8 (Krantz et al., 2004; Tonkin et al., 2004; Musio et al., 2006; Deardorff et al., 2007; 
Deardorff et al., 2012a; Deardorff et al., 2012b). 
Thanks to a large and international cooperation we were able to assemble an extensive cohort 
of patients with CdLS or CdLS-overlapping phenotypes. By means of different techniques, 
patients were analyzed for the presence of mutations in the five CdLS-associated genes. This 
analysis led us to the identification of 109 mutations in NIPBL, 8 mutations in SMC1A, 15 
mutations in SMC3 and 10 mutations in HDAC8. Mutations in RAD21 were not identified in 
any of the investigated patients. All the observed alterations affect highly conserved amino 
acids, and were reported to be disease causing by different bioinformatic tools (PolyPhen-2, 
SIFT and Mutation Taster). Our newly identified variants raise the total number of mutations 
affecting NIPBL to 470, thus confirming the cohesin loader as the major gene of the syndrome, 
being responsible for more than half of CdLS cases (Fig.33) 
(http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NIPBL). Out-of-frame deletions or insertions 
together with missense substitutions are the most frequent observed alteration. As previously 
reported, patients harboring mutations in NIPBL tend to present with a more canonical 
phenotype characterized by marked growth retardation and developmental delay and by typical 
facial dysmorphisms. Limb malformations are also observed with a high frequency, in 
particular in association with out-of-frame alterations (Selicorni et al., 2007). Importantly, nine 
patients were found to carry mutations in a mosaic condition. The identified mosaic alterations 
comprise two splicing variants, two out-of-frame deletions, three missense substitutions and 
two nonsense mutations. Hence, no correlation can be established between the onset of 
mosaicism and the type of alteration. Interestingly, the nine patients carrying the mosaic 
variants present with a broad range of clinical features. Classic facial dysmorphisms and severe 
limbs reductions were also observed in this group of patients, thus indicating that the mosaic 
condition is not necessarily correlated to a mitigation of the effect of the mutation. The 
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assessment of whether mosaicism arises from a somatic mutation after fertilization or from 
negative selection of the cells harboring the mutation is currently an issue of utmost 
importance. All together, our findings strengthen the need for the integration of highly sensitive 
sequencing technologies into routine molecular work up as well as the importance to 
investigate DNA samples derived from more than one tissue, given that mutations are 
frequently not detectable on blood DNA.  
All together, the remaining four genes SMC1A, SMC3, HDAC8 and RAD21 account for about 
10-15% of CdLS cases (Fig.33). Our work raises the total number of mutations in these genes 
to 49, 16, 38 and 8, respectively (Borck et al., 2007; Deardorff et al., 2007, Liu et al., 2009; 
Limongelli et al., 2010; Mannini et al., 2010; Pié et al., 2010; Hoppman-Chaney et al., 2011; 
Deardorff et al., 2012a; Deardorff et al., 2012b; Gervasini et al., 2013; Feng et al., 2014; Kaiser 
et al., 2014; Gil-Rodriguez et al., 2015; Lebrun et al., 2015; Goldstein et al., 2015; Yuan et al., 
2015). Albeit all kinds of variants have been reported for HDAC8, the vast majority of 
mutations in SMC1A or SMC3 do not disrupt the reading frame of the protein, thus suggesting 
that the pathogenic mechanism associated with alterations of the core subunits of the cohesin 
complex may act through a dominant negative effect. Nevertheless, very recently, one 
alteration of the splicing and two 4-bp deletions, all resulting in a premature stop, have been 
identified in SMC1A in three female patients presenting with epilepsy and with few or absent 
CdLS features (Goldstein et al., 2015; Lebrun et al., 2015). These findings might indicate that 
haploinsufficiency of SMC1A might lead to a phenotype different from CdLS, whereas a 
dominant negative pathomechanism results in CdLS or CdLS-overlapping phenotypes.  
The 34 patients herein described with mutations affecting SMC1A, SMC3 and HDAC8 present 
with a milder or less typical phenotype: several facial features commonly observed in typical 
CdLS are in fact absent or infrequent in this group of patients. For instance, synophrys is often 
absent or subtle, the nasal tip is often bulbous or broad and the nasal bridge is less frequently 
depressed. Nevertheless, these patients present with a broad range of phenotypes, for which a 
variable degree of cognitive impairment and a severe verbal and motor developmental delay are 
the only unifying features. The clinical heterogeneity is even wider in the presence of mutations 
affecting the X-linked genes SMC1A and HDAC8. Male patients with mutations in these genes 
usually display a highly recognizable, more homogeneous and severe CdLS phenotype. 
Conversely, females present with a broad range of clinical features and a variable degree of 
severity of the syndrome. In this context, the wide clinical expressivity observed in females 
might also be correlated with the extent of the skewing of the X-inactivation towards the 
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normal allele. Consistent with this possibility, a skewed X-inactivation was observed on blood 
DNA of almost all female patients harboring mutations in SMC1A and HDAC8. 
Interestingly, clinical comparisons between patients sharing the same mutations revealed that 
the displayed clinical signs are not identical. For instance, the two male patients harboring the 
single amino acid deletion p.E488del in SMC3 presented with a similar craniofacial appearance 
during infancy, but showed a different progression of the clinical signs with aging (Deardorff et 
al, 2007; Gil-Rodrìguez et al., 2015). The two patients also displayed a different degree of 
cognitive impairment and developmental delay, with one patient being unable to speak at the 
age of 23 years and with limited motor development and the other patient working as an adult. 
Similarly, the clinical comparison between two female patients carrying the variant 
p.V58_R62del in SMC1A indicated a similar limb involvement and the presence of GERD and 
myopia in both patients (Deardorff et al., 2007; Gervasini et al., 2013). Nevertheless, 
distinguishable clinical features were also observed: the patient described by Deardorff and 
colleagues displayed pulmonary stenosis, hearing loss and a borderline cognitive impairment 
whereas our patient presented with ptosis, highly arched palate, teeth malformations and a 
moderate degree of intellectual disability. Likewise, despite the existence of similar 
craniofacial features in the presence of the p.G320R substitution in HDAC8, the male patient of 
our cohort presented with pulmonary stenosis and vesicoureteral reflux, whereas the patient 
described in Deardorff et al., 2012b displayed hearing loss and seizures. These clinical 
comparisons reveal that the genetic background given by the combination of polymorphic and 
non polymorphic variants as well as the influence of environmental factors might contribute to 
the definition of the clinical phenotype, thus making the genotype-phenotype correlation 
complicated and difficult to interpret. All together, these findings suggest that the range of 
clinical features caused by alterations of the cohesin complex might be significantly broader 
than previously appreciated.  
 
Figure 33. Graphical representation of the contribution exerted by each of the identified CdLS-genes. Up to date, 470 
mutations have been observed in NIPBL, 45 in SMC1A, 16 in SMC3, 38 in HDAC8 and 8 in RAD21. Nevertheless, it is still not 
possible to identify the molecular cause of the syndrome in a large group of CdLS patients 
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OVERALL AND ALLELE-SPECIFIC EXPRESSION OF 
THE SMC1A GENE 
Several studies have contributed to define the genetic cause of CdLS (Krantz et al., 2004; 
Tonkin et al., 2004; Musio et al., 2006; Deardorff et al., 2007; Deardorff et al., 2012a; 
Deardorff et al., 2012b). Nevertheless, little is known on the pathogenic mechanism underlying 
the syndrome. In case of heterozygous mutations affecting the level of the synthetized NIPBL 
gene product, upregulation of the wild type allele as an attempt to compensate for the lower 
expression of the mutant allele was demonstrated in both mouse and humans cells (Dorsett and 
Krantz, 2009; Kawauchi et al., 2009).Compensatory upregulation of the wild type allele is even 
more relevant for the X-linked gene SMC1A, which partially escapes X inactivation in humans 
and show a variable expression of the allele lying on the inactive X chromosome (Carrell and 
Willard, 2005). The portion of the allele that escapes X inactivation further contributes to the 
wide variability of features observed in female patients with SMC1A mutations. Therefore, the 
analysis of the expression of SMC1A is highly relevant for the clinical evaluation of female 
patients.  
Previous studies in heterozygous females could demonstrate the presence of the mutant 
transcript and of normal levels of the SMC1A protein in patients (Musio et al., 2006; Liu et al., 
2009; Revenkova et al., 2009). In addition, Gimigliano and colleagues demonstrated the 
incorporation of the mutant SMC1A into the cohesin complex (Gimigliano et al., 2012). 
Therefore, in order to ascertain the pathogenic mechanism associated with SMC1A, we 
analyzed the overall and allele-specific expression of the gene in the healthy population and in 
female patients with X-linked CdLS, carrying SMC1A mutations. So far, different studies 
reported a variable but always higher expression of SMC1A in females as compared to males 
(Craig et al., 2004; Johnston et al., 2008; Liu et al., 2009). In line with the previous data, our 
Real Time PCR experiments could demonstrate that the level of expression of the SMC1A 
transcript in healthy female controls is 50% higher than in healthy males. In agreement with the 
results of the transcriptional analysis, our western blot experiments demonstrated for the first 
time that the level of the SMC1A protein in females is 44% higher than in males. The same 
analysis, when extended to our cohort of female patients, revealed that there are no significant 
differences between healthy females and CdLS patients in the total amount of the SMC1A 
protein, thus consolidating the hypothesis that the pathogenic mechanism associated to 
missense mutations in SMC1A in female patients is not linked to haploinsufficiency, but to a 
probable dominant negative effect.  
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Albeit the overall amount of SMC1A remains unchanged, a previous study reported a different 
level of expression of the wild type and mutant alleles in a single patient (Liu et al., 2009). For 
this reason, we carried out a pyrosequencing assay on a group of six SMC1A-mutated females 
and 15 SMC1A-heterozygous controls in order to assess the expression ratio between the wild 
type and mutant alleles. This analysis revealed that all female patients expressed the two alleles 
differentially. In point of fact, patients always expressed the wild type allele at higher levels as 
compared to the mutant allele, with an average ratio between wild type and mutant allele of 2:1. 
Our findings partially justify the existence of patients with mutations in SMC1A displaying 
very mild or borderline phenotypes. For this reason, the assessment of the expression ratio 
between the wild type and the mutant allele becomes of utmost importance for the 
comprehension of the wide clinical expressivity in females.  
Taken into account the dominant negative effect enacted by the altered SMC1A protein, it 
might be possible that level of expression of the mutant allele may act as modulator of the 
CdLS phenotype. In agreement with this hypothesis, patient 1, who presented with a borderline 
phenotype, displayed the lowest expression level of the mutant SMC1A allele. Anyhow, a clear 
correlation between the expression levels of SMC1A and the severity of the phenotype could be 
established only by extending the analysis to a larger cohort, and especially to those borderline 
cases that are frequently overlooked except for the identification of the affected progeny.   
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BEYOND COHESINOPATHIES: MUTATIONS IN 
CHROMATIN-ASSOCIATED FACTORS AS GENETIC 
CAUSE OF CdLS-OVERLAPPING PHENOTYPES 
 
 
Figure 34. (A-I) Facial features of patients with CdLS or CdLS-overlapping features harboring mutations in transcription 
factors different from cohesins. (J-L) Phenotypical appearance of patients affected by multisystem developmental disorders 
different from CdLS, who were found to carry mutations in CdLS-related genes 
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The employment of high-throughput sequencing techniques has helped to shed light on part of 
the missing heritability in CdLS: mosaicism has been proven to be responsible for a high 
percentage of CdLS cases previously found to be negative for the presence of mutations in the 
five CdLS genes investigating DNA extracted from blood. The role of mosaicism is of 
particular relevance in association with NIPBL, but few mosaic cases have also been reported 
for SMC1A, SMC3 and HDAC8 (Huisman et al., 2012; Ansari et al., 2014; Baquero-Montoya et 
al., 2014; Braunholz et al., 2015). Despite the significant role played by mosaicism, the 
molecular cause for more than 20% of CdLS patients is still unknown. In this context, genes 
functionally related to cohesin or genes responsible for clinical entities partially overlapping 
with CdLS might both be able to cover this missing heritability. 
Exome sequencing has recently led to the identification of mutations in chromatin-associated 
factors different from cohesin in patients with CdLS or CdLS-overlapping phenotypes 
(Fig.34A-I). These transcriptional regulators, which are responsible for the onset of other 
multisystem developmental disorders, include EP300, AFF4 and KMT2A (Woods et al., 2014; 
Izumi et al., 2015; Yuan et al., 2015). In addition, next generation sequencing techniques 
targeted to the exome or to a selected set of genes allowed us to identify mutations in our 
cohort of patients in ANKRD11  (Parenti et al., 2015) and in different subunits of the SWI/SNF 
complex, namely SMARCB1, ARID1A and ARID1B. EP300 is a transcriptional coactivator 
which is known to be responsible for Rubinstein-Taybi syndrome (Roelfsema et al., 2005). 
KMT2A is instead associated to Wiedemann-Steiner syndrome and encodes for a transcription 
factor that acts as a lysine-specific methyltransferase (Jones et al., 2012). The ANKRD11 gene 
codes for the ankyrin repeat-containing protein 11, a repressor of the transcription of nuclear 
receptors’ target genes and mutations in this gene are associated with KBG syndrome (Sirmaci 
et al., 2011). Mutations in different subunits of the SWI/SNF complex, responsible for 
chromatin remodeling, were instead associated to Coffin-Siris syndrome (Santen et al., 2012). 
Lastly, mutations in AFF4, a core component of the super elongation complex, were found to 
be responsible for a new syndrome that phenotypically overlaps with CdLS named CHOPS 
(Izumi et al., 2015). Correspondingly, mutations in the cohesin gene SMC1A were recently 
reported in two patients with a clinical diagnosis of Wiedemann-Steiner syndrome (Fig.34J-K) 
(Yuan et al., 2015). Similarly, we report herein of a mutation in the cohesin loader NIPBL in a 
patient with Coffin-Siris syndrome (Fig.34L).  
Interestingly, although the aforementioned disorders are de facto distinct syndromes, they all 
share some phenotypical features such as a variable degree of intellectual disability, a general 
developmental delay, growth impairment and some craniofacial features including 
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brachycephaly and thick and arched eyebrows. Despite the presence of some relatively unique 
features for each syndrome, the observed phenotypical overlap suggests the existence of a 
common pathophysiology among these disorders. In this context, it is worth to be noted that the 
genes responsible for these syndromes are all involved in the regulation of gene expression. In 
addition, our yeast two hybrid experiments could prove a physical interaction between the 
SWI/SNF subunit SMARCB1 and the cohesin genes NIPBL and SMC3, whereas Lopez-Serra 
and colleagues demonstrated that the cohesin loader NIPBL and the SWI/SNF complex 
cooperate in order to maintain nucleosome depletion at target regions of the genome in yeast 
(Lopez-Serra et al., 2014). It is therefore tempting to speculate that mutations in the previously 
mentioned genes might be responsible for the alteration of the expression of functionally 
interconnected sets of genes, thus giving a molecular explanation for the similarities observed 
among the different syndromes. For this reason,Yuan and colleagues recently conceived the 
term “transcriptomopathies” to describe those syndromes sharing core clinical features as a 
consequence of global disturbances in the transcriptional regulation of the cell (Fig.35). 
In conclusion, mutations in different transcription factors can result in clinical pictures that are 
difficult to distinguish from each other, thus indicating a wide pleiotropy that should be taken 
into account while addressing the clinical diagnosis. The extensive clinical and functional data 
reported in here indicate the existence of limitations of the current “state of the art” for the 
molecular diagnosis of CdLS and CdLS-overlapping phenotypes. The clinical heterogeneity of 
the syndrome and the numerous differential clinical diagnoses strongly suggest the integration 
of next generation sequencing technologies into the routine molecular diagnostics in order to 
enable a higher sensitivity and the concomitant analysis of multiple sets of genes. 
 
Figure 35. Mutations in different chromatin-associated factors are responsible for the so called “transcriptomopathies”, that 
is syndromes caused by alterations of interconnected sets of genes that  share a variable degree of cognitive impairment and a 
general developmental delay 
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PERSPECTIVES 
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An extensive clinical and molecular heterogeneity characterizes CdLS. The identification of 
new genes responsible for overlapping phenotypes and the recognition of the important role 
played by mosaicism has helped to shed light on the molecular basis of the syndrome. 
Nevertheless, further advances are needed to fully understand the causative molecular 
mechanisms. In this context, additional experiments will be addressed to the resolution of the 
following issues: 
 
 Definition of the mechanisms responsible for the onset of mosaicism 
 Analysis of the expression mechanisms responsible for the onset of different phenotypes 
in the presence of the same DNA alteration 
 Definition of the pathogenic mechanisms underlying the syndrome in the presence of 
out-of-frame deletions in SMC1A 
 Identification of new causative genes 
 Characterization of the interaction of SMARCB1 with NIPBL, with particular attention 
to the following aspects: 
• Does the presence of mutations disrupt the interaction between the two proteins? 
• Does MAU2 influence the interaction between NIPBL and SMARCB1? 
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